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ABSTRACT OF THE DISSERTATION 
 
Population-level impact of antiretroviral therapy 
and mixed strains of Mycobacterium tuberculosis 
on tuberculosis transmission 
 
by 
Yeonsoo Baik 
Doctor of Philosophy in Epidemiology 
University of California, Los Angeles, 2019 
Professor Anne W. Rimoin, Chair 
 
 
Current tuberculosis (TB) control measures face two challenges: the human immunodeficiency virus 
(HIV) co-epidemic and genotypic complexity of Mycobacterium tuberculosis (MTB) via exogenous 
reinfection.  To address the former, antiretroviral therapy (ART) is known to be the single most effective 
TB prevention method among people living with HIV. Despite the substantial evidence supporting its 
clinical effects, ART has an unknown population-level impact on the TB epidemic. The second challenge–
MTB reinfection—complicates management of the epidemic when multiple MTB strains infect a single 
host (mixed infection). Though mixed infection is known to be associated with poor clinical outcomes, 
the transmission mechanisms associated with mixed infection have not yet been explored. To better 
understand and overcome these two challenges for TB control, this dissertation aims to estimate and 
simulate the population-level impact of ART on TB incidence and to propose possible transmission 
mechanisms of mixed infections. The dissertation study setting is Botswana, a middle-income southern 
iii 
 
African country with high TB and HIV burden. Despite its limited resources, Botswana’s combination of 
high disease prevalence and progressive public health programs provide an ideal study setting to 
research TB and up-to-date TB control programs.  This dissertation will provide implications that are 
relevant to Botswana’s current TB control practices and will deliver valuable insights for other high TB- 
and HIV-burden countries. Chapter 1 is a brief overview of TB. Chapter 2 examines community-level risk 
factors, including an ART intervention, for incident TB risk in individuals. Chapter 3 develops an 
individual-based model of TB transmission and HIV co-infection to simulate the long-term impact of ART 
scale-up interventions on TB incidence. Finally, Chapter 4 explores possible transmission mechanisms 
associated with mixed MTB infection. 
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Chapter 1. Introduction 
Overview 
The overall goal of this dissertation is to address human immunodeficiency virus (HIV) and 
mixed infection, two factors that have complicated tuberculosis (TB) epidemiology and control measures 
in high TB and HIV burden settings. People living with HIV (PLHIV) have 20-fold higher risk of TB 
infection. Antiretroviral therapy (ART) uptake among PLHIV is important for viral suppression, immune 
system repair, and prevention of opportunistic infections, including Mycobacterium tuberculosis (MTB). 
On the other hand, regardless of HIV, a large proportion of new TB cases have been attributed to recent 
transmission. In a high TB-burden setting, recent transmission implies high likelihood of exposure to 
multiple MTB strains, which increases risk of mixed MTB infection. 
Botswana, the setting for this dissertation, is one of the highest TB- and HIV-burden countries 
globally. In 2017, the incidence of TB was 300 cases per 100,000 individuals. Forty-eight percent of new 
cases were HIV co-infected. The first two studies described in this dissertation focus on the effect of ART 
as a joint prevention measure against HIV and TB. The first study examines the individual TB incident risk 
associated with the community-level ART coverage rate and other community-level characteristics such 
as socioeconomic status and healthcare accessibility within communities. The second study evaluates 
the effect of an ART scale-up intervention on future trends in the incidence of TB in Botswana. Using 
agent-based models, future trends in TB incidence were simulated until 2035, the year that the World 
Health Organization (WHO)’s global End TB strategy set its target indicators. The last study explores the 
burden of mixed MTB infection and possible transmission mechanisms using molecular epidemiology 
data.  
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Background 
TB disease 
TB is an infectious disease caused by MTB almost exclusively by person-to-person airborne 
transmission. Transmission occurs when MTB is aerosolized from an infected source to a contact who is 
at risk for infection. (1) Depending on the immune status of the infected host and the host’s interactions 
with MTB, TB can lead to diverse clinical and pathological presentations. Latent infection is caused by 
bacteria persisting in a non-replicating form. An infected host harboring actively replicating bacteria may 
have no clinical symptoms or may develop active TB disease. Active TB disease is infectious and its 
presumptive symptoms are cough, fever, night sweats, weight loss, or/and coughing up blood. 
Symptoms may last from weeks to months.(2) After initiating the standard TB treatment for at least 6 
months, the symptoms and infectiousness of TB diminishes rapidly.(3)  
Global burden of TB and HIV 
In 2017, ten million individuals developed TB and 1.3 million individuals died from TB (excluding 
HIV-related cases).(2) Though new TB cases were reported from all over the world, 87% were reported 
from the top 30 high TB-burden countries, which are mostly low- and middle-income countries. HIV 
infection has fueled the TB epidemic: PLHIV have a 20-times higher risk of developing TB and experience 
faster disease progression within the first few months. Of the new cases in 2017, 10% were HIV-
associated TB cases and 300,000 TB deaths were among PLHIV. Given that the majority of PLHIV live in 
low- and middle-income countries (4) and more than 50% of HIV-associated TB cases were from African 
countries, TB prevention and treatment in PLHIV is an urgent priority in resource-limited settings. (2)  
Among the current TB/HIV joint interventions, antiretroviral therapy (ART) is the single most 
effective way to reduce the TB burden in PLHIV. (5) ART is a combination of antiretroviral drugs to 
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suppress HIV replication and reconstitute the immune system. Using CD4 T-cell level as an immune 
biomarker, the protective effect of ART on TB incidence among PLHIV has been studied widely. (6) As 
the immune system is restored, the CD4 T-cell level is increased, preventing fast TB disease progression 
and decreasing severity of TB disease. Accordingly, the WHO has recently scaled up its use of ART. 
Previously, only PLHIV whose CD4 T-cell level was lower than 200 cells/mm3 were eligible to receive 
HIV. Now, all PLHIV can be offered ART without restriction based on CD4 T-cell level. 
 Since the ART intervention was introduced and scaled up, the world has increased average ART 
uptake rate from 40% to 79% among PLHIV who know their HIV status. (7) With higher levels of ART 
coverage, the protective effect of ART is expected to spill over and impact the population beyond PLHIV. 
It is anticipated that ART can not only decrease the HIV viral load and HIV transmission in communities, 
but also reduce the force of TB infection from the decreased burden of HIV-associated TB cases. (8, 9) 
However, the impact of ART in communities beyond PLHIV has not been studied widely. Though 
nationwide surveillance shows that an increase in ART coverage rate was associated with decreased TB 
notification rates, (10-12) gaps in current knowledge exist regarding the implication of ART as a public 
health intervention against the TB epidemic. Chapter 2 incorporates individual-level TB risk and 
population-level ART coverage rate to provide a public health perspective on ART and TB incidence. 
Chapter 3 projects the long-term trends for the TB epidemic under a hypothetical scenario in which the 
ART scale-up intervention was successfully conducted. 
Molecular epidemiology of MTB and mixed infection 
 Molecular genotyping is a DNA-based technology for the detection of the genetic constitution at 
a molecular level. In the field of MTB research, molecular epidemiology harnesses molecular genotyping 
to identify different MTB strains and evaluate transmission dynamics in time and space.(13) Molecular 
epidemiology can be used to demonstrate exogenous reinfection after primary MTB infection.(14-16) 
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Historically, recurrent TB was believed to develop through endogenous reactivation from a latent 
infection or relapse after treatment. (7,9) Exogenous reinfection by different MTB strains represents a 
new pathway. This new discovery implies that primary infection may confer partial immunization against 
subsequent infections, challenging current treatment and vaccine development. Further, molecular 
epidemiologic studies have shown that a large proportion of new TB cases occur as a result of recent 
transmission. (17, 18) Risk of reinfection depends on local TB prevalence – the more MTB strains 
circulating in a community, the higher the risk of being exposed and reinfected. (14, 15) Based on these 
findings from molecular epidemiology, TB control strategies have begun to emphasize identification of 
TB transmission chains so that they may be interrupted. (19) Recent TB transmission and reinfection is 
particularly relevant among PLHIV. (15) Up to 80% of new TB cases in high TB- and HIV-burden settings 
have been attributed to reinfection from exogenous MTB strains. (20) 
Mixed MTB infection occurs when multiple distinct MTB strains infect a single host in a single 
disease episode. Recently, techniques for molecular genotyping have become more sensitive for 
detecting different MTB strains. This progress has facilitated the identification of mixed infections. 
Evaluation of the transmission mechanisms by which mixed infections occur may explain the 
transmission dynamics of MTB. For instance, mixed infections have provided evidence supporting 
reinfection as a prominent driver of the TB epidemic.(14) Further, mixed infection may help explain poor 
treatment outcomes. For example, when MTB strains within one host have different drug susceptibility, 
treatment exposure may lead to multidrug-resistant TB. 
Despite the broader relevance of mixed infection in public health, published evidence describing 
mixed infection have focused on high risk populations. Theoretically, HIV infection renders a host more 
vulnerable to mixed infection; however, the relationship between HIV and mixed MTB infection has not 
been well-established. Chapter 4 addresses this gap, explores the burden of mixed infection in the 
general population, and evaluates possible transmission mechanisms of mixed infection both with and 
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without HIV co-infection. Chapter 4 not only fills the current knowledge gap but also evaluates existing 
interventions, which mainly focus on halting recent transmission.  
Study setting  
Botswana is one of the highest TB- and HIV-burden countries globally. In 2017, the incidence of 
TB was 300 cases per 100,000 individuals. Forty-eight percent of new cases were HIV co-infected. Prior 
to 1990, TB incidence in Botswana was declining. However, the emergence of HIV in Botswana has 
caused the TB epidemic to resurge.(21) Botswana is a middle-income country that is both economically 
and politically stable. Although it is relatively resource-limited, Botswana is one of the few African 
countries that took the initiative with progressive public health programs, such as free TB and HIV 
treatment. Botswana introduced free and universal ART in 2002 for individuals with CD4 T-cell counts 
lower than 200 cells/mm3. It raised the CD4 threshold to 250 cells/mm3 in 2008, to 350 cells/mm3 in 
2013, and, in accordance with the WHO’s “Treatment for All” strategy, to all PLHIV regardless of CD4 
level in 2016.(22) In addition, the government of Botswana dedicated substantial efforts to 
strengthening its health infrastructure, supporting development of healthcare facilities, laboratories, 
information systems, professional human resources, and healthcare workers training.(22) In 2003, 
Botswana National TB Control Program (BNTP) adopted the directly observed therapies (DOTs) strategy. 
(21) In 2016, Xpert MTB/RIF became the primary tool for diagnosis in lieu of conventional smear 
microscopy. As a result of these efforts, Botswana achieved the UNAIDS 90-90-90 goal in 2017: 90% of 
PLHIV will be tested for HIV, 90% of whom will be on ART, 90% of whom will achieve viral 
suppression.(23) As Botswana achieved success in HIV control, improved TB control followed. The TB 
incidence in Botswana decreased from 620 per 100,000 (75% HIV co-infection) in 2002 to 300 per 
100,000 (48% HIV co-infection) in 2017.(24, 25) 
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Chapter 2. Impact of Community-level Antiretroviral Therapy on Tuberculosis Incidence 
Abstract 
Background 
The risk of tuberculosis (TB) depends in part on community-level factors beyond individual risk factors. 
Antiretroviral therapy (ART) significant decreases the risk for TB among HIV-infected patients. The scale-
up of ART uptake may also affect the TB epidemic at the community level. We explored community-level 
factors, including ART rollout, for individual TB risk. 
Methods 
We used a nationally representative sample based on the Botswana AIDS Impact Survey 2013 (BAIS IV), 
aimed at determining HIV incidence and prevalence in the country. ART uptake and other 
sociodemographic data were collected at the individual-level through the survey, and summarized as 
community-level variables. We used generalized estimating equations to identify predictors of self-
reported newly diagnosed TB in the past 12 months. 
Results 
Of 8,231 eligible participants, 7,750 (94%) responded to the TB questionnaire and 297 (4%) reported 
having been diagnosed with TB in the past 12 months. Overall, 9% of individual risk of TB development 
was attributable to within-community clustering. We observed reduced odds of acquiring TB (odds ratio 
[OR] = 0.69, 95% confidence interval [CI] = 0.40 – 1.21) in communities with high ART coverage (median 
= 57.1%, interquartile range [IQR] = 50.0 – 67.9%) compared to those with low ART coverage (median = 
33.1%, IQR = 20.0 – 33.6%). The odds of TB were decreased (OR = 0.68, 0.46-1.01) in communities with 
high employment rates (median = 94.1%, IQR = 91.2 – 96.4%) compared to those with low employment 
rates (median = 82.3%, IQR = 78.8 – 85.3%). The odds of TB were decreased (OR = 0.74, CI = 0.51-1.08) 
among communities with high access to social and medical services (median = 41.3%, IQR = 36.0-48.6%) 
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compared to those with low access (median = 22.2%, IQR = 15.0 – 26.7%).  
Conclusions 
Community-level ART uptake and socioeconomic factors may affect individual TB incidence but larger 
studies are needed to generate more precise estimates. Public health and social interventions that 
address both individual and contextual factors may have a stronger influence on TB rates compared to 
those exclusively focused on individual TB risk factors.   
11 
 
Introduction 
Tuberculosis (TB) is one of the most common opportunistic infections among people living with HIV 
(PLHIV). Globally, about 10% of incident TB cases were attributed to PLHIV in 2017. (1) HIV antiretroviral 
therapy (ART) is considered one of the forefront TB preventive measures among PLHIV. (2, 3) ART 
prevents HIV-associated TB by anti-mycobacterial immune restoration and CD4-cell count recovery. (2) 
Indeed the reduction in TB incidence among PLHIV due to ART uptake has been confirmed in many 
observational cohorts. (4) In a recent systematic review, PLHIV on ART had a 65% decrease in TB 
incidence (3, 5), and those who started ART at earlier stages in their disease fared even better, with up 
to an 80% lower incidence. (6) Despite the significant decrease in the risk for TB among PLHIV on ART, 
their risk for TB is likely to be time-dependent and still remains higher than their HIV uninfected 
counterparts. (6, 7)  
 
The protective effect of ART against TB infection may have a population-wide effect in addition to the 
individual-effect. ART rollout is expected to have the potential for decreasing the TB incidence at the 
population-level, by reducing the community-level HIV viral load, which was used as the population-level 
marker of the potential for HIV transmission. (8) Moreover, early initiation ART among PLHIV may either 
reduce the chance of latent TB advancing to TB disease or delay TB disease progression. (9) The reduced 
HIV-associated TB incidence may lower the force of TB infection in communities overall, and therefore 
reduce the TB incidence risk. However, in contrast to extensive individual-level observational studies, 
empirical data regarding the population-wide impact of ART on TB incidence risk in individuals are 
scarce. (4) According to mathematical modeling studies, immediate ART treatment on HIV infection 
would reduce the HIV prevalence and the HIV-associated TB incidence in nine African countries. (10) The 
expansion of ART usage would decrease the country-level TB case notification rate both among HIV-
infected and -uninfected individuals, although it would happen much more slowly in the uninfected 
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group. (11-14)  
 
To reach the long-term epidemiologic targets for global TB control, socioeconomic determinants of TB 
must also be addressed. (15) Many observational cohort and ecologic studies have found an association 
between social deprivation and TB risk. (15) Indeed, population-based health and socioeconomic 
indicators, such as neighborhoods’ lower education, (16) poverty, (16-18) unemployment (19), or 
locality type (17, 20) have shown associations with TB incidence ecologically. However, only few studies 
have estimated the extent to which an individual’s risk of developing TB depends on community-level 
determinants. (21) In addition, the effect of socioeconomic deprivation has not been explored in the 
context of community ART rollout.  
 
In this study, we aimed to estimate the association of individual risk of TB development with 
community-level of HIV prevalence, community-level ART coverage rate, and community-level 
socioeconomic factors, after accounting for individual-level determinants. We also estimated the 
contribution of general contextual effects to individual variation in TB incidence risk.  
 
Methods 
Study settings and data 
We conducted our study in Botswana, one of the highest TB and HIV burdened countries worldwide, 
with a reported TB incidence of 300 per 100,000 in 2017. (22) Of the new TB cases, 48% were HIV-
positive, and of those 91% were on ART. (22) In an attempt to control its HIV and TB epidemics, 
Botswana implemented free, universal access to ART starting in 2002. Botswana has updated the ART 
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eligibility criteria from the PLHIV whose CD4 cell count is lower than 200 cells/mm3 in 2002 to CD4 cell 
count lower than 350 cells/mm3 in 2013. The scope of its universal ART policy was expanded in 2016 by 
the implementation of a “treat all” strategy, which aimed to provide ART to all PLHIV regardless of their 
CD4 count. (23)  
 
This study employed a cross-sectional design using the Botswana AIDS Impact Survey 2013 (BAIS IV) 
data, a two-stage sampling nationwide, population-based HIV survey conducted between January 2013 
– April 2014. HIV prevalence was estimated among the population aged 6 weeks to 64 years, and 
demographic and behavioral questionnaires were asked to the population aged 10 through 64 years. 
Dried blood spot (DBS) specimens were collected from all participants aged 18 months or older and 
screened for HIV antibodies using ELISA test kits (Vironostika-HIV Uni-Form II plus O and Murex) as per 
Botswana National Policy on HIV testing. DBS specimens from infants less than 18 months were tested 
for HIV virus antigen using DNA PCR Roche technology upon agreement. (24) 
 
Measurement 
The main outcome of this study was the probability of newly diagnosed TB within a one-year period. The 
information was collected as a binary variable through a self-answered question of “Have you ever been 
diagnosed with tuberculosis in the last 12 months?” 
 
The main exposure of interest at the community-level was the ART coverage rate scaled by HIV 
prevalence in the community. In this study, community was defined as a unit of enumeration area (EA), 
the smallest geographical analysis unit available, on which the survey sampling was based. To apply the 
survey sampling, the number of individuals were weighted with the sampling weights from the survey. 
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The HIV prevalence in each community was measured as the weighted number of HIV-infected 
individuals divided by the weighted size of the population in the community. The estimated HIV 
prevalence in the community was categorized by tertiles and grouped into ‘low’ from the lowest tertile 
(=<10.7%) and ‘moderate/high’ from the two highest tertiles (>10.7%). Within the ‘moderate/high’ HIV 
prevalent communities, ART coverage rate was measured as the weighted number of HIV-infected 
individuals who are on ART” divided by the weighted size of the local population. Then it was divided 
into ‘high’ if higher than the median rate (40%) and ‘low’. As a result, the main exposure of community-
level ART coverage rate by HIV prevalence had three categories: high ART uptake in moderate/high HIV 
prevalence, low ART uptake in moderate/high HIV prevalence, and low HIV prevalence.  
 
We used a different cut-off for the HIV and ART rate based on 2013 country-level estimates. Specifically, 
the estimated HIV rate was classified into two groups (high vs. low), based on the estimated country-
level average of HIV prevalence (16.5% in 2013). (23) Similarly, the estimated ART rate was 
dichotomized using the country-level average of 41.6% in 2013. (23). These values were then applied to 
create the three group ART coverage rate by HIV prevalence exposure variable value for each 
community with reference to the country-level cutoffs.  
 
Other exposures of interest at the community-level included the proportion of higher education 
receivers (defined as tertiary education, including university/college, beyond university/college, 
technical/vocational, institution of health sciences, and brigade) and the proportion of unemployment. 
As household income was not available from the data, these two variables were used as proxies for 
socioeconomic status. The proportion of higher education receivers was estimated as the weighted 
number of individuals who have completed tertiary education divided by the weighted size of the 
population in the community. The proportion of unemployment was estimated as the weighted number 
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of individuals who are currently unemployed divided by the weighted size of the population in the 
community.  
 
The exposure of interest at the individual-level was HIV infection status. The HIV lab test results were 
obtained for all survey subjects upon agreement. If the subjects either had a positive lab test or were 
currently taking ART (as uninfected individuals would not be under the ART according to the 
guideline),the subjects were classified as HIV positive.  
 
Both individual- and community-level covariates were explored. At the individual-level this included age, 
gender, education level, marital status, employment status, alcohol consumption in the last 12 months, 
and TB treatment history. At the community-level, the focus was on variables that can measure area-
based socioeconomic status: the proportion of individuals receiving financial aid, the proportion of 
individuals who answered that social/medical services were available in their own community, and the 
proportion of individuals ever having accessed social/medical services in their own community. 
Social/medical services included programs for home based care, orphan care, people living with 
HIV/AIDS, assistance of the destitute (e.g. psychosocial support to underprivileged members of the 
community), free ART treatment, prevention of mother-to-child HIV transmission (PMTCT), voluntary 
counseling and testing (VCT) and routine HIV testing (RHT), TB prevention and treatment, family 
planning and sexual and reproductive health (SRH), safe male circumcision (SMC), and others. Each of 
the proportions was calculated as the weighted number of individuals who received financial 
aid/endorsed the availability of or accessed any of the above social/medical programs in their own 
community divided by the weighted size of the population in the community. The locality type, namely 
whether the community was urban (cities, towns, and urban villages) or rural (rural districts), was also 
included.  
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Statistical analyses 
To characterize the sample we provided descriptive statistics at both the individual and community 
levels. Categorical variables were presented as counts and percentages, while continuous variables were 
described with means, standard deviation, medians, and interquartile ranges (IQRs); summaries for 
individual-level variables were weighted according to the sampling scheme. To examine the association 
between community-level exposures and individual-level TB risk, while adjusting for both individual- and 
community-level factors and accounting for the non-independence of individual observations within a 
community, we fit a logistic regression model using generalized estimating equations (GEE) as our 
primary analysis. (21, 25) Multilevel logistic regression modeling was used for a secondary analysis to 
quantify the variation in TB risk due to community-level effects beyond the individual-level effects. (26) 
 
Model specification 
Considering the relatively low prevalence of the TB outcome, we used a model selection procedure to 
reduce the number of covariates in order to avoid data sparsity and multi-collinearity. (27) The variable 
selection was done based on the following four steps. First, we drew the causal direct acyclic graph 
(DAG) to display the theorized relationships among the variables, which were available in the BAIS IV 
dataset and potentially important for estimating the effect of interest [Figure 2]. Second, we estimated 
the odds ratio (OR) and 95% confidence interval (CI) from the univariate regression for each variable in 
order to compare the model-based estimates from the BAIS IV data set and the expected inferential 
trends. (28) Third, we excluded the covariates with a large percentage of missing data in order to 
decrease noise and sparse-data bias. Lastly, we estimated the degree of collinearity, both between the 
exposure and the covariates and among the covariates. (27) The covariates included in the final model 
are age, sex, HIV infection, proportion of high education receivers in the community, unemployment 
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rate in the community, and social and medical service accessible rate in the community.  
 
Measure of Association 
A generalized linear model with GEE and a logistic link function was applied to estimate the marginal or 
population-average effect of each characteristic, applying the BAIS-IV survey weights to make the data 
representative of the entire Botswana population. In addition to the given individual-level survey 
weights, the cluster-level weights were set to be equal under the assumption that the first stage 
sampling probabilities were the same for all clusters. This aligned with the assumption that the sampled 
clusters would have no significantly different community-level factors from the not sampled clusters. 
The GEE approach was used to estimate population-level average ORs. to quantify the heterogeneity in 
the effect of cluster-level variables (26), and to estimate robust standard errors, which are more 
appropriate in the presence of clustering. (26, 29) 
 
Measure of Variance 
A two-level generalized linear mixed model (GLMM) with a logistic link function was used to measure 
the general contextual effects. (26) The variance partition coefficient (VPC) or intra-class correlation 
(ICC) estimated the magnitude of clustering effect. The original individual-level survey weights were re-
scaled to individual standardized weights, first in order to compute subset weighted estimates, and 
second to avoid biased covariance parameter estimates in the multilevel model; the latter is important 
when multi-stage survey sampling involves unequal probabilities of selection at any of the hierarchical 
levels, which was the case in this study for cost and administrative reasons. (30, 31)  
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All statistical analyses used SAS, version 9.4. (2018 SAS Institute Inc., Cary, NC, USA) We did not use a 
pre-specified threshold for statistical significance. (32)  
 
Results 
Among the sampled individuals, 8,231 (84%) responded to the survey and consisted of the study 
population. Of those, 7,750 (94%) responded to the outcome question and the rate of self-reported new 
TB in the past 12 months was 4%. [Figure 1] There were 215 EAs included in the clustered sampling; 
however, we used 214 EAs after excluding one community whose sample size and sample probability 
was missing. Across 214 communities, the median TB incidence rate was 3.0% (interquartile range [IQR] 
= 0% – 5.6%). 
 
After applying the sample weights, 16% were HIV positives, 44% of which were under ART. More than 
half were aged between 10 and 40 years old (74%) and female (53%). [Table 1] The HIV prevalence and 
ART uptake rate for the whole sample was 13.9% and 40.0%, respectively. When categorizing the 
communities with the data-based cutoffs, the median HIV prevalence among the moderate/high HIV 
prevalence and high ART uptake communities was median = 20.0% (IQR = 15.5 – 27.6%), and the median 
ART rate was 60.0% (IQR = 50.0 – 71.4%). [Table 2] Whereas, when categorizing the communities with 
the cutoffs based on the national estimates in 2013, the median HIV prevalence among the 
moderate/high HIV prevalence and high ART uptake communities was median = 24.6% (IQR = 19.7 – 
30.9%), and the median ART rate was 57.1% (IQR = 50.0 – 67.9%). 
 
Subjects diagnosed with TB in the last 12 months were more likely to be elderly, male, alcohol 
consuming, and HIV positive than those who were not diagnosed. [Table 3] The median TB incidence 
19 
 
across communities with moderate/high HIV prevalence and high ART rate, moderate/high HIV 
prevalence and low ART rate, and low HIV prevalence was 2.9% (IQR = 0 – 5.3), 3.3% (IQR = 1.0 – 5.9%), 
and 2.6% (IQR = 0 – 5.1%), respectively. [Table 4] 
 
The univariate associations between the variables and TB incidence showed the hypothesized trend as 
presented in the DAG. [Table 5; Figure 2 (a)] However, the following predictors were excluded from the 
multivariable models due to large amounts of missing data: alcohol use (71% missing) and the 
proportion of individuals receiving financial aid (64% missing). The locality type was excluded from the 
final model since it showed strong collinearity with the community-level HIV and ART rates, individual-
level HIV status, age group, community-level high education rate, and the access to social/medical 
service in the community. The final set of exposures of interest and covariates are shown in Figure 2 (b).  
 
We examined the odds of TB as a function of individual level exposure after adjusting for other 
individual- and community-level covariates in the GEE model. The odds of TB development were 2.89 
times higher (95% CI = 1.90 – 4.39) among PLHIV compared to HIV uninfected individuals. [Table 6] 
Using the data-based cutoffs, the population-level average OR for being newly diagnosed with TB in the 
prior 12 months was 0.82 (95% CI = 0.52 – 1.28) in communities with high HIV prevalence but good ART 
coverage, and 0.92 (95% CI = 0.49 – 1.74) in communities with low HIV prevalence, compared to 
communities with high HIV prevalence but low ART coverage. The ORs changed to 0.69 (95% CI = 0.40-
1.21) and 1.02 (95% CI = 0.60 – 1.75), respectively, using the cutoffs based on the national estimates. 
Under the cutoffs based on the national estimates, communities with high rates of employment, higher 
education, and service access had ORs of 0.68 (95% CI = 0.46 – 1.01), 0.90 (95% CI = 0.61 – 1.32), and 
0.74 (95% CI = 0.51 – 1.08) for incident TB, respectively, compared to their counterparts. [Table 6]  
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Based on the VPC (or ICC), 8.6% of the individual variation in the underlying odds of TB development 
was due to systematic differences between communities after adjusting for individual HIV infection, age, 
and sex.  
 
Discussion 
To our knowledge, this is the first study using multilevel analyses to investigate the empirical evidence 
for a protective effect of community-level ART coverage on the individual risk of TB. The main outcome 
of TB diagnosis in the prior 12 months was collected through a self-reported question. Without 
microbiological diagnosis, TB incidence may have been overestimated (4%), given that the annual TB 
incidence was 300 per 100,000 in 2017 in Botswana. It is possible that any prevalent TB cases, who 
might be diagnosed more than 12 months ago, was included. There also may be self-reported false 
positive TB cases. These prevalent or false TB cases may have contributed to the long-term, diluting the 
ART’s preventive effect in the community. 
 
Our findings show that the residents of communities with high ART uptake rates have 18 – 31% lower 
odds of developing TB when compared to hypothetically comparable individuals living in communities 
with low ART uptake rate. However, there was a high level of statistical uncertainty in this estimate as 
indicated by the wide 95% CIs. The lack of a stronger community-level effect may have been due to the 
low ART rate among the HIV positive individuals, resulting in an average 41% of ART uptake rate at the 
community-level. The BAIS IV survey was conducted before the adoption of the “Treatment for All” 
strategy in Botswana in 2016, and our findings are aligned with the report from the national ART registry 
that 42% of HIV positive individuals with CD4 cells below 350/uL were on ART in 2010. (33) This low 
population ART coverage rate may not have been sufficient for conferring a larger preventive effect at 
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the population-level in the communities. (13) In the future, we can repeat this study in the latest BAIS V 
data, which was conducted in 2018 but not available to the public yet, to assess the community impact 
of HIV testing and treatment on the TB incidence. 
 
Our findings highlight the complexity in understanding the community-level preventive effect of ART on 
TB, given a context of co-existent counter-factors that may cancel one another out. (3) We hypothesized 
that the individuals living in the communities with the high ART uptake rate may have the lower risk of 
TB incidence. It was ecologically shown in the previous Malawi studies of scale-up ART and TB 
notification rates at the country-level, as the reduced force of TB infection in communities lower the 
burden of TB not only in HIV-infected but also in HIV-uninfected populations. (7, 11) However, we could 
not rule out a possibility of an opposite dynamic: specifically, the proportion of people at high risk for TB 
may increase as the proportion of PLHIV increases in communities due to their extended life expectancy 
and their TB-associated immune reconstitution inflammatory syndrome (TB-IRIS), potentially leading to 
higher TB incidence. (34, 35) TB-IRIS is an early complication of ART. Rapid immune restoration by ART 
can cause new presentation of a previously subclinical TB infection or can cause exaggerated 
inflammatory response to TB during the initial months of ART. TB among PLHIV on ART with stronger 
immune systems may also resemble that of TB among HIV-uninfected people, which is characterized by 
higher bacterial burden, high rates of cavitation and, potentially, higher levels of infectiousness. (36) The 
improved detection of TB during the ART-based care may also be another mechanism. (3, 34) Further 
studies prospectively following-up non-presumptive TB patients, or incorporating the time-dependent 
effect of ART intervention on individuals’ TB diagnosis patterns could unravel the impact of these 
opposite effects.  
 
Our findings also highlight that the community-level social determinants are just as important as the 
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community-level HIV prevalence and ART coverage rate in terms of the impact on individual TB risk. The 
odds of TB for individuals living in communities with lower proportion of unemployment and higher 
proportion of accessible social/medical service were decreased. The perspective of TB as a disease 
driven by social determinants is not new; however, to meet the United Nation’s (UN) Sustainable 
Development Goals (SDGs) by 2030 and the World Health Organization’s (WHO) goal of ending TB 
epidemic by 2035, actions targeting low SES factors should be prioritized in health interventions and 
should receive as much attention as ART rollout from the TB control perspective. (37, 38)  
 
Inclusion of higher-order contextual variables indicated a moderate degree community-level effects on 
individual TB risk as indicated by a 8.6% ICC. (A 20% ICC in a multilevel logistic model is typically 
interpreted as indicating moderately high between-group heterogeneity and/or within-group 
homogeneity. (39)) This measure of variance may be underestimated in that we did neither include a 
thorough set of community-level variables nor have the high ART coverage rate. The TB incidence across 
the communities also had small variation. This moderate degree of clustering in the communities still 
aligns with other studies, which identified a high chance of transmission chain of TB in the community 
outside the households, especially in a high-incidence setting. (40, 41) Local variation in the community-
level variables or spatial heterogeneity was also found in other studies. However, the effectiveness of 
the spatial screening of TB targeting high-burden communities was estimated mostly in low TB/HIV 
burden countries. (42)(41) While our finding of a strong association between TB risk and individual-level 
HIV infection status aligns with many previous studies, the decrease in this association after considering 
the contextual predictors suggests an important impact of community-level factors that may confound 
the relationship between HIV and TB risk at the individual level. (43) Public health interventions should 
incorporate approaches that address contextual influences at the community-level as well as the 
individual-level. (44) 
23 
 
 
Our study had several limitations. The final analysis was based on a parsimonious approach to model 
specification. Because few incident cases of TB were reported in the population-based data, attempting 
to fit a full model led to a failure of convergence, regardless of the estimation method. Hence using a 
minimal set of covariates in the final model was unavoidable. However, we were still able to address big 
picture questions effectively and the study results from parsimonious models can be extrapolated and 
applied to other low- or middle-income countries in similar social environments and conditions with 
greater stability than over-fit models. Due to the cross-sectional nature of the survey, we could not 
consider the temporal factor between ART initiation and TB diagnosis. As mentioned above, ART uptake 
comes prior to the TB incidence. Although we excluded individual-level ART use from the list of 
covariates, there may be a certain degree that variations in individual ART administration may disturb 
the association the association between community-level ART and TB risk appearing weaker than it 
should. In particular, ART may be initiated late in the disease course in sub-Saharan African countries, 
after many HIV-associated TB infections have already occurred. (2) This would push the association 
between population-level ART coverage rate and TB incidence in the opposite direction to what we 
hypothesized. In addition, TB-IRIS after ART initiation among HIV patients treated for TB may give the 
misleading impression that ART uptake increases TB risk. (45) Our data set had high rates of missing 
values for several known risk factors for TB, such as alcohol consumption and financial burden (social 
deprivation), and other important risk factors, such as smoking, were not included in the BAIS-IV survey 
and hence could not be included in our final model. Household-level clusters were also not considered 
because the BAIS-IV survey did not provide the household-level sampling weights and did not collect the 
household-level risk factor information, such as household income and the number of household 
members (or household density). Therefore, residual confounding may have had an effect over our 
observed associations. To supplement the lack of household clustering, we counted the new TB cases 
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reported from the same household using the most proxy variable among the available variables. Less 
than 10% of cases were from the same household, and we concluded that disregarding household 
clustering and factors might not affect our result significantly. Finally, creating the community-level 
measurements by aggregating the individual-level information was unavoidable, but may suffer from 
potential misclassification bias.  
 
Despite these limitations, our study results highlight the importance of community-level social 
determinants in driving the TB epidemic in high-incidence settings. Therefore, public health 
interventions should target improvements in the overall socioeconomic status of the community as well 
as individual-level risk factors. We recommend that future studies be conducted in a community with 
high ART uptake rates and estimate ART’s preventive effect among the general population in the 
community regardless of HIV infection status.  
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Tables  
Table 1. Individual-level characteristics of the study population (N=8,168 of 8,231) * 
    Unweighted Weighted 
  
N = 8,168 N = 1,067,086.13 
  
N % N % 
Age 
    
 
10_19 2,102 26 285,036 27 
 
20_29 2,146 26 286,905 27 
 
30_39 1,816 22 215,226 20 
 
40_49 1,153 14 145,274 14 
 
50_59 748 9 105,230 10 
 
60_64 203 2 29,415 3 
Gender 
    
 
Male 3,828 47 498,288 47 
 
Female 4,340 53 568,798 53 
Highest Level of Education 
    
 
Primary 2060 25 276,873 36 
 
Secondary 4,052 50 513,631 52 
 
**Tertiary 1,441 18 188,173 19 
 Missing 615 8 . . 
Marital Status 
    
 
Married/Co-living 2,881 35 356,466 36 
 
Never Married 4,561 56 613,313 61 
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Separated/Divorced/Widowed 245 3 33,916 3 
 Missing 481 6 . . 
Employment Status 
    
 
Employed 4,283 52 536,255 79 
 
Unemployed 1,062 13 141,860 21 
 Missing 2823 35 . . 
Alcohol during the Last 12 Months 
    
 
Yes 1,394 17 184,779 61 
 
No 976 12 120,321 39 
 Missing 5798 71 . . 
HIV infection     
Positive 1,271 16 168,711 16 
Negative 6,897 84 898,375 84 
HIV status and ART    
 
 
HIV Positive and ART 558 7 74,647 7 
 
HIV Positive but no ART nor NA 713 9 94,064 9 
 
Negative/Unknown HIV 6,897 84 898,375 84 
TB diagnosis within 12 months*** 
    
 
Yes 293 4 39,739 4 
 
No 7,394 96 963,956 96 
TB treatment history* 
    
 
Ever 182 62 25,440 64 
 
Currently 24 8 3,488 9 
 
Never 87 30 10,811 27 
32 
 
TB; tuberculosis, ART; Antiretroviral therapy, NA; Not available 
*Number of people used in the weighted analysis was different (N=8,168) from the raw number of 
people (N=8,231) 
** Education tertiary included college, university, vocational, military, and above (according to the 
survey guideline) 
*** Divided by the Number of TB Patients (N=293) 
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Table 2. Community-level characteristics of the study Population (N=214 of 215) 
 
N (%) Mean (standard 
deviation) 
Median Interquartile Range 
Population size per community* 214 (99) 6295.6 (4832.7) 5426.4 2651.4 – 8489.0 
Locality type**     
Urban 161 (75) - - - 
Rural 78 (36) - - - 
HIV Prevalence (%) 214 (99) 15.4 (8.7) 13.9 9.5 – 19.2 
ART Rate among HIV Positives (%) 209 (98) 41.2 (25.1) 40.0 27.5 – 58.3 
HIV and ART rate by the data-based cutoffs 214 (99) HIV ART HIV ART 
Moderate/high HIV & High ART 72 (34) 22.4 (10.1) 62.5 (14.9) 20.0 (15.5 – 27.6) 60.0 (50.0 – 71.4) 
Moderate/high HIV & Low ART 71 (33) 19.3 (7.5) 27.0 (12.9) 17.3 (13.7 – 21.8) 31.7 (20.0 – 36.5) 
Low HIV 71 (33) 6.8 (3.1) 34.9 (36.5) 7.6 (4.9 – 9.4) 33.1 (0.0 – 60.7) 
HIV and ART rate by the cutoffs based on the 
national estimates 
     
Moderate/high HIV & High ART 52 (24) 26.4 (9.7) 59.4 (12.7) 24.6 (19.7 – 30.9) 57.1 (50.0 – 67.9) 
Moderate/high HIV & Low ART 37 (17) 23.8 (7.0) 27.0 (11.2) 21.4 (18.2 – 27.2) 33.1 (20.0 – 33.6) 
34 
 
Low HIV 125 (59) 9.7 (4.2) 38.3 (32.5) 10.0 (7.1 – 13.3) 33.3 (0.0 – 60.0) 
Proportion of High Education Receivers (%) 214 (99) 15.84 (13.9) 11.5 6.0 – 23.0 
High 112 (52) 28.87 (15.2) 25.0 16.7 – 36.5 
Low 102 (48) 5.18 (3.7) 5.6 1.6 – 8.1 
Proportion of employment (%) 214 (99) 12.57 (7.8) 11.6 6.2 – 17.2 
High 113 (53) 94.0 (3.2) 94.1 91.2 – 96.4 
Low 101 (47) 81.5(5.7) 82.3 78.8 – 85.3 
Proportion of Individuals in Financial Aid 
Households (%) 
214 (99) 4.00 (6.5) 0 0 – 7.1 
High 76 (36) 11.14 (9.0) 9.7 5.6 – 13.5 
Low 138 (64) 0 (0) 0 0 
Proportion of Individuals Available to 
social/medical service in own community (%) 
214 (99) 50.78 (29.7) 58.3 27.4 – 76.8 
High 106 (50) 77.01 (10.5) 77.8 68.2 – 85.0 
Low 108 (50) 23.10 (22.5) 23.9 0 – 46.9 
Proportion of Individuals Ever Accessible to 
social/medical service in own community (%) 
214 (99) 32.09 (13.1) 32.1 24.5 – 40.9 
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High 104 (49) 43.42 (9.7) 41.3 36.0 – 48.6 
Low 110 (51) 20.40 (8.2) 22.2 15.0 – 26.7 
TB; tuberculosis, ART; Antiretroviral Therapy, NA; Not available, All “Low” categories in the group-level estimates include 0 count 
* Weighted number 
** A community may have both urban and rural locality type depending on sub-communities 
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Table 3. The study population included in the weighted generalized equation estimating models (N= 
7,687 of 7,750) 
    TB diagnosed 
within 12 
months 
Not diagnosed 
within 12 
months 
Weighted TB in 
12 months 
Weighted non-
TB in 12 months 
N 
 
293 7,394 39,739 963,956 
  
n % n % n % n % 
Age 
        
 
10_19 32 11 1939 26 4,716 12 261,752 27 
 
20_29 53 18 1,974 27 6,736 17 262,722 27 
 
30_39 72 25 1,632 22 8,899 22 192,413 20 
 
40_49 71 24 1,023 14 8,684 22 130,476 14 
 
50_59 53 18 650 9 9,126 23 90,849 9 
 
60_64 12 4 176 2 1,578 4 25,744 3 
Gender 
        
 
Male 154 53 3,384 46 21,867 55 437,935 45 
 
Female 139 47 4,010 54 17,873 45 526,021 55 
Highest Level of Education 
        
 
Primary 77 26 1,876 25 9,393 23 254,020 26 
 
Secondary 112 38 3,694 50 14,310 36 464,647 48 
 
Tertiary 42 14 1319 18 4,416 11 174,406 18 
Marital Status 
        
 
Married/Co-living 126 43 2,755 37 16,317 41 340,149 35 
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Never Married 149 51 4,412 60 21,722 55 591,592 61 
 
Separated/Divorced/ 
Widowed 
18 6 227 3 1,701 4 32,215 3 
Employment Status 
        
 
Employed 177 60 3,852 52 22,255 56 483,323 50 
 
Unemployed 40 14 948 13 6,428 16 124,428 13 
Alcohol during the last month 
        
 
Yes 71 24 1,323 18 11,081 28 173,698 18 
 
No 44 15 932 13 4,627 12 115,695 12 
HIV infection         
 Positive 109 37 1,155 16 15,123 38 152,884 16 
 Negative 184 63 6,239 84 24,616 62 811,072 84 
HIV status and ART  
        
 
HIV Positive and ART 66 23 492 7 9,989 25 64,657 7 
HIV Positive but no ART nor 
NA 
43 15 663 9 5,134 13 88,227 9 
 
Negative/Unknown HIV 184 63 6,239 84 24,616 62 811,072 84 
TB treatment history         
 Currently 24 8 . . 3,488 9 . . 
 Ever 182 62 . . 25,440 64 . . 
  Never 87 30 . . 10,811 27 . . 
TB; tuberculosis, ART; Antiretroviral therapy, NA; Not available 
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Table 4. Incidence rate of tuberculosis (%) 
 Mean Standard 
Deviation 
Median IQR 
Tuberculosis Incidence 3.6 3.5 3.0 0.0 – 5.6 
Locality type     
Urban 3.4 3.3 3.0 0.0 – 5.6 
Rural 3.9 3.9 3.0 1.0 – 5.6 
HIV and ART rate by the data-based cutoffs     
Moderate/high HIV & High ART 3.6 3.6 2.9 0 – 5.3 
Moderate/high HIV & Low ART 3.9 3.4 3.3 1.0 – 5.9 
Low HIV 3.3 3.6 2.6 0 – 5.1 
HIV and ART rate by the cutoffs based on the national 
estimates 
    
Moderate/high HIV & High ART 3.4 4.0 2.7 0 – 5.3 
Moderate/high HIV & Low ART 3.7 4.4 3.0 0 – 5.6 
Low HIV 3.2 3.6 2.6 0 – 4.9 
Proportion of employment     
High 3.2 3.2 3.0 0 – 5.3 
Low 4.0 3.8 3.0 1.2 – 5.9 
Proportion of high education receivers     
High 3.3 3.3 2.7 0 – 5.6 
Low 3.8 3.7 3.3 0 – 5.3 
39 
 
Proportion of individuals in households under financial 
aids 
    
High 4.1 3.6 3.2 1.0 – 6.1 
Low 3.2 3.4 2.9 0 – 4.9 
Proportion of individuals available to social/medical 
service 
    
High 3.2 3.6 2.5 0 – 4.3 
Low 4.0 3.4 3.7 0 – 5.8 
Proportion of individuals accessible to social/medical 
service 
    
High 3.5 3.3 2.8 1.0 – 5.6 
Low 3.7 3.8 3.1 0 – 5.2 
ART; Antiretroviral therapy 
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Table 5. Odds ratios from the univariate generalized equation estimating model for tuberculosis 
incidence 
  
Odds Ratio Confidence Interval 95% 
Individual-level Measures 
   
HIV Infection Positive 3.26 2.29 4.63 
 
Negative Reference 
Age Group 10 ~ 19 Reference 
 
20 ~ 29 1.42 0.82 2.46 
 
30 ~ 39 2.57 1.59 4.14 
 
40 ~ 49 3.69 2.28 5.99 
 
50 ~ 59 5.58 2.93 10.62 
 
60 ~ 64 3.40 1.46 7.91 
Sex Male 1.47 1.05 2.05 
 
Female Reference 
Education Group     
 
Primary Reference 
 
Secondary 0.83 0.54 1.28 
 
Tertiary 0.69 0.37 1.28 
Marital Status Married/Cohabitation Reference 
 Single 0.77 0.57 1.04 
 Separated/divorced/widowed 1.10 0.52 2.35 
Alcohol Consumption Yes 1.60 0.94 2.71 
 
No Reference 
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Employment Employed 0.74 0.49 1.12 
 
Unemployed Reference 
Community-level Measures 
   
Locality type Urban 0.67 0.44 1.00 
 Rural Reference 
HIV and ART rate by the data-
based cutoffs 
Moderate/high HIV & High ART 0.87 0.51 1.47 
Moderate/high HIV & Low ART Reference 
Low HIV 0.72 0.43 1.20 
HIV and ART rate by the cutoffs 
based on the national 
estimates 
Moderate/high HIV & High ART 0.75 0.39 1.44 
Moderate/high HIV & Low ART Reference 
Low HIV 0.82 0.44 1.55 
Proportion of employment High 1.35 0.88 2.07 
 
Low Reference 
Proportion of high education 
receivers 
High 0.84 0.54 1.31 
Low Reference 
Proportion of individuals in 
households under financial aids 
High 1.42 0.98 2.04 
Low Reference 
Proportion of individuals 
available to social/medical 
service 
High 0.82 0.58 1.16 
Low Reference 
Proportion of individuals 
accessible to social/medical 
service 
High 0.80 0.57 1.12 
Low Reference 
42 
 
ART; Antiretroviral therapy 
Missing categories were not included in the regression 
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Table 6. Odds ratios from the generalized equation estimating model for tuberculosis incidence 
  Community-level HIV and ART 
rates by the data-based cutoffs 
Community-level HIV and ART rates 
by the cutoffs based on the national 
estimates 
  
Odds 
Ratio 
Confidence Interval 
95% 
Odds 
Ratio 
Confidence Interval  
95% 
Individual-based Measures 
    
   
HIV Infection Positive 2.76 1.84 4.14 2.89 1.90 4.39 
 
Negative Reference . . Reference . . 
Age Group 10 ~ 19 Reference . . Reference . . 
 
20 ~ 29 1.28 0.74 2.20 1.28 0.74 2.19 
 
30 ~ 39 1.90 1.14 3.18 1.90 1.13 3.17 
 
40 ~ 49 2.61 1.59 4.30 2.63 1.60 4.32 
 
50 ~ 59 4.66 2.52 8.62 4.66 2.52 8.61 
 
60 ~ 64 2.96 1.25 7.00 3.01 1.27 7.11 
Sex  Male 1.58 1.14 2.19 1.58 1.14 2.19 
 
Female Reference . . Reference . . 
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Community-based Measures   
   
   
HIV and ART Rate  Moderate/high HIV & High ART 0.82 0.52 1.28 0.69 0.40 1.21 
Moderate/high HIV & Low ART Reference . . Reference . . 
Low HIV 0.92 0.49 1.74 1.02 0.60 1.75 
Proportion of employment High 0.69 0.44 1.07 0.68 0.46 1.01 
Low Reference . . Reference . . 
Proportion of high education 
receivers 
High 0.92 0.58 1.44 0.90 0.61 1.32 
Low Reference . . Reference . . 
Proportion of individuals ever 
access to social/medical service 
in their community 
High 0.72 0.49 1.06 0.74 0.51 1.08 
Low Reference . . Reference . . 
ART; Antiretroviral therapy 
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Figures 
Figure 1. Flow chart (The absolute numbers prior to weighting) 
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Figure 2. Multilevel Directed Acyclic Graph 
(a) Suggestive epidemiologic path from antiretroviral therapy to tuberculosis incidence 
 
 
(b) Final model between antiretroviral therapy to tuberculosis incidence 
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Chapter 3. Antiretroviral therapy scale-up to reach the 2035 tuberculosis control target – agent-based 
modeling 
Abstract 
Background 
Botswana introduced the ‘Treatment for All’ antiretroviral therapy (ART) intervention in 2016 and as of 
2017 has achieved 86% ART coverage among the 84% known HIV-positive people. As individual-level 
evidence has shown CD4 dependent risk of TB disease progression, this study aimed to estimate the 
nationwide TB incidence by 2035 attributable to the ART intervention.  
Design/Methods 
We developed an individual-based model of TB transmission and pathogenesis including HIV co-
infection. The model fit to Botswana’s historical country-level TB incidence and mortality over time from 
2000 to 2017. The projected TB incidence at 2035 before and after the introduction of ART scale-up was 
compared. ART coverage was estimated and held constant from the Botswana AIDS Impact Survey in 
2013 and the UNAIDS 90-90-90 goal (90% ART coverage among the 90% known HIV positives), 
respectively. The projected TB incidence at 2035 from these scenarios was compared to the baseline 
and the 2015 estimates. 
Results 
Before the ART scale-up, ART coverage was 44%, and the projected TB incidence in 2035 was 350.9 per 
100,000. After the ART scale-up increased the ART coverage up to 81%, the projected TB incidence in 
2035 was 255.6 per 100,000. The ART scale-up reduced TB incidence by 2% compared to the baseline 
(260.0 per 100,000 at 2035) and 22% compared to the 2015 estimates.  
Conclusions 
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The ART scale-up intervention contributed to reduction in the TB incidence over time in Botswana, 
although the impact of the ART intervention alone was modest.   
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Introduction 
Botswana was one of the few African countries which introduced the free and universal antiretroviral 
therapy (ART) program in 2002 and ‘Treatment for All’ ART intervention in 2016. (1,2) As of 2018, it has 
achieved 72% ART coverage rate among the known HIV positive individuals. (2) ART contributed to 
immune recovery among HIV infected individuals by shifting the CD4 count upward, showing more than 
70% protective effect in TB incident risk. (3,4) The achievement of the high ART coverage is expected to 
affect HIV control as well as TB epidemic in Botswana, where more than 48% of the new TB cases were 
HIV-associated TB. (5)  
 
The relationship between CD4 cell count and TB risk in HIV infected individuals has been explored 
quantitatively. (6) Due to  immune reconstitution inflammatory syndrome, increased TB incidence may 
be observed at the time of ART initiation, approximately during the first four months (7); however, CD4 
cell count showed a strong predictor for TB risk. Although CD4 cell count among HIV infected individuals 
has been used as an important marker in ART initiation guidelines, (6) the long-term impact of ART 
scale-up on the TB epidemic is unknown yet. Botswana’s national-level model of TB transmission 
integrating with within-host disease dynamics among HIV co-infected individuals can help evaluate the 
contribution of the ART scale-up to the future TB epidemic trend. One global target goal of the World 
Health Organization (WHO)’s End TB Strategy is the reduction of the TB incidence by 90% by 2035 
compared to the incidence in 2015. 
 
In this study, we aimed to build an individual-based TB transmission model specific to the Botswana 
setting and accounting for CD4 cell count dependent TB risk. We simulated the long-term trend of TB 
incidence by 2035 with two scenarios: before and after the introduction of the ‘Treatment for All’ ART 
intervention in 2016. The projected TB incidence at the year of 2035 from each of the two scenarios was 
50 
 
used to estimate the degree to which the ART scale-up intervention brings Botswana close to the WHO’s 
2035 global target goal.  
 
Methods 
We developed a country-level TB transmission and pathogenesis model for Botswana, applying agent-
based modelling. The TB and HIV coinfection simulation files were available through the Epidemiologic 
MODeling software (EMOD) package v2.18. (8) In addition to the TB and HIV coinfection dynamics, we 
incorporated a TB diagnosis algorithm and treatment pathway into the model following the Botswana 
National TB Program (BNTP) guideline. The overall model schematic was visualized in Figure 3. 
Description of model 
Agent-based modeling 
Agent-based modeling is a computational model simulating interactions of micro-entities or agents. 
(9,10) The changes on agents and interactions over time affect the macro-system which consists of the 
agents. Each agent is assigned a variety of independent properties such as age, gender, and HIV 
infection, and behaviors such as healthcare seeking. That agent-based modeling accounts for unique 
characteristics of each agent and follows its trajectories over time gives it advantages over traditional 
compartmental modeling. First, agent-based modeling can be flexible with the heterogeneous 
individuals (11) whereas compartmental modeling assumes homogeneous and equal characteristic in 
the fraction of a population who move states at the same time. To account for heterogeneity, 
compartmental modeling requires a lot of compartments, sometimes more compartments than the 
sample size.  
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Second, agent-based modeling allows each agent to move from state to state, using decision rules based 
on its properties. The decision rules have randomness, which can reflect the realistic situations more 
flexibly. (11) For example, a susceptible agent will not necessarily be infected to TB even after exposed. 
While compartmental modeling determines the rates at which the fraction of a population moves from 
each compartment. For example, in agent-based modeling, tracking agents what time they enter and 
leave the state or how long they stay in the state can reflect the time-dependent variables such as CD4 
cell count and HIV disease progression. Compartmental modeling is memoryless, meaning that everyone 
in the same state is equivalent – how long the agent (here, an individual) was latent infected with TB 
does not change the probability of the individual progressing to the active TB disease status. Everyone in 
the same state comes in and out the state at the same rate determined by, as known as ordinary 
differential equation.  
 
Therefore, third, agent-based modeling can apply intervention to agents sequentially and have strong 
predicted power reflecting complicated real-world situations better than compartmental modeling. 
(10,11) 
 
Disadvantages are that agent-based modeling is highly computational and difficult to calibrate and 
justify its assumptions. Applying the EMOD software and existing simulation types help to perform 
agent-based modeling less laboriously.  
Heterogeneity in populations 
Each individual was assigned a variety of independent properties that could impact transmission, such as 
year of birth, current age, sex, fertility rates (if female), mortality rates, propensity to seek care, HIV 
infection, and ART uptake.  
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TB natural history 
Each individual was tracked from the time he/she enters the simulation (e.g. birth) until the time he/she 
leaves the simulation. The individual was located at one state (e.g. susceptible (S), exposed (E), infected 
(I), or recovered(R)) in the beginning and transitioned to another state at fixed time steps in discrete 
time intervals (e.g. one day in our model). (11) Moving from one state to another follows a random 
chance of binomial distributions, or by Bernoulli random draws. This allows the model to reflect each 
individual’s (not the fraction of the population) different probability of moving from state to state. This 
is also a way to build randomness into the model. The transition process is described in mathematical 
equations as below (11): 
 
Equation: S(t + δ) = Binomial ((S(t), Pi)  
I(t + δ) = I(t) + Binomial (S(t),Pi) - Binomial (I(t),Pr) 
R(t + δ) = R(t) + Binomial (I(t),Pr) 
, where t is time, δ is a simulation type step (by default δ is one day), Pi = 1 - e ^ (λδ) is the 
probability, λ = (βI)/N is the force of infection, β is the transmission rate for S becoming I, Pr = 
1 – e ^ (γδ) is the probability of recovery, and γ is the rate at which I move to the R state. 
 
To be specific, the pool of susceptibles was configured by individual properties and initial population set-
up. The susceptible individuals were exposed to TB pathogens and moved on to latent infection at a rate 
that differed by both host and pathogen’s interactive characters. The incubation period of pathogens 
and the immune function of individuals worked to specify the relationship between time since infection 
and onset of infectiousness. (11) The latent infection progressed to exhibit active symptoms. The onset 
of active TB symptoms usually coincides with the timing of becoming infectious or transmitting the 
disease. We did not consider other dynamics of infectiousness, and started transmission from active TB 
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in the model. According to the BNTP guideline, active TB disease patients flowed into diagnosis and 
treatment pathway, allowing imperfect diagnosis sensitivity (depending on smear positivity) and 
treatment efficiency (using dropout rates). The list of main configured parameters and their values used 
in the model is in Table 7. 
HIV and ART  
HIV incidence estimates for Botswana were first, specified by age and sex over time based on the 
Spectrum HIV model, free available software through Avenir Health. (12) HIV infection was randomly 
distributed across the population. In our model, the HIV distribution did not represent a HIV 
transmission mechanism. For example, whether it happens through sexual or mother-to-child vertical 
transmission was not reflected. Instead, HIV status and history of ART program participation were 
tracked for each individual, and enabled the model to adjust the prevalence of HIV over time and 
disease progression rates among TB/HIV co-infected individuals. (13) HIV infected individuals were 
assigned CD4 cell counts as a strong predictor for TB risk. The CD4 cell counts were continuous yet 
associated with TB risk based on mutually exclusive ranges: CD4 level <200 cells/µL, 200 cells/µL ≤ CD4 
level <250 cells/µL, 250 cells/µL ≤ CD4 level <350 cells/µL, 350 cells/µL ≤ CD4 level <500 cells/µL, and 
500 cells/µL ≥ CD4 level.  
 
The CD4 cell counts declining over time without ART were determined by the model. ART played a role 
of increasing the CD4 cell counts by construction. The HIV infected individuals were assigned either ART 
uptake or no ART, according to the ART eligibility guideline in Botswana. The ART eligibility has been 
updated overtime in Botswana and the model reflected this change by introducing ART at the simulated 
year of 2002 for HIV positives with CD4 level <200 cells/µL, year of 2008 for CD4 level <250 cells/ µL, 
year of 2013 for CD4 level <350 cells/µL, and year of 2016 for all HIV positives regardless of CD4 level. 
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(1) The model estimated ART coverage rate was adjusted to match to the country-level ART coverage 
rates. For example, the HIV testing and ART coverage rates were plugged in to match the estimates from 
the UNAIDS report (released in 2018), which was 86% and 86% * 84% = 72%, respectively. (2) Once 
eligible, an individual sampled his/her ART initiation date from an exponential distribution with one-year 
mean. (13) ART dropout rate was not counted assuming small dropout rate and its small impact on the 
TB epidemic at the national-level. (14) HIV epidemic and ART intervention were introduced at simulated 
years of 1990, and 2002, respectively, and parameterized based on the data. (1)  
TB pathways: from healthcare seeking to treatment outcome 
Individuals who entered the active TB disease status started seeking healthcare. Here the healthcare 
seeking behavior corresponded with self-identification of TB symptoms (cough, fever, night sweats, and 
weight loss). The healthcare seeking rate was calibrated. During the healthcare seeking step, the model 
reflects sensitivity of existing diagnostics according to smear and HIV status. The model accounts for 
dropout in the TB care cascade, with the dropout rate as the fixed parameter. Individuals who failed 
treatment or received a false negative test came back to re-seek care. The re-seeking healthcare rate 
was set as the same healthcare seeking rate for simplicity of illustration. 
 
Both diagnosis and treatment had two different periodic arms in order to account for different 
sensitivity of diagnostic tools and treatment efficacy, respectively. The model reflected the adoption of 
GeneXpert in year 2016 replacing smear diagnostics, and directly observed therapies (DOTs) in year 
2003, according to the Botswana’s national guideline. (15) In other words, individuals who flowed into 
the diagnosis before 2016 were diagnosed with the acid-fast bacillus smear microscopy test, those who 
flowed into the diagnosis after 2016 were diagnosed with GeneXpert.  The model reflected changes in 
treatment success from 65% before the introduction of DOTs in 2003 to 90% after DOTs. The individuals 
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who were diagnosed as active TB or who failed TB drug regimen were sent or re-sent to the TB 
treatment. Sensitivity of diagnostic tools and treatments also differed by sputum smear positivity and 
HIV positivity. [Table 7] 
Other factors 
Other CD4-dependent activation rates, especially related to pathogen-related (e.g. incubation period) 
and general TB disease-related characteristics (e.g. increased disease progression rate by CD4 cell 
count), were configured. (9,16) The list of these parameters is given in [Table8].  
Calibration 
The model simulation was calibrated to the incidence and mortality in Botswana for 18 years from 2000 
to 2017. (17) We allowed the model to seed and run for 100 years of burn-in period from 1990 during 
the beginning of HIV epidemic, as a purpose of converging TB incidence and mortality trend. The 
calibration process was iterated until the simulation was compatible to the reference incidence and 
mortality data for 18 years, which were extracted from the WHO database. [Figure 4] The model was 
calibrated based on the input historical population-wide data, such as general life expectancy, birth 
rates, death rates (all cause and non-HIV/TB-related death rates), population growth rates, population 
structure by age and sex from 1990 to 2017, and HIV incidence from 1970 to 2017. These data were 
extracted from the Spectrum HIV model, the global health database provided by the Institute for Health 
Metrics and Evaluation (IHME). (18) The population size and age structure were from World Meter and 
World Bank. (19)  
 
Three parameters were calibrated: base infectivity, proportion of TB disease fast progressors, and mean 
time (days) to diagnosis from symptom. None of these parameters were measured directly on the 
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country level in Botswana. These parameters contribute to the dominant effects on the population-level 
TB transmission. (16) Bae infectivity was re-scaled by multiplying by the base infectious period (=365 
days, which is set default in the EMOD) to the basic reproduction number (R0). R0 indicates the number 
of secondary infections that would arise from one primary infectious source or individual under the 
situation where all individuals are susceptible without effective interventions. It is usually determined by 
the mechanism of interaction between individuals and specific to each disease’s transmission mode. 
(11) The progression of infection within a host is another major component of disease transmission. The 
progression rate was set slow or fast representing the distribution of progression rates from latent to 
active. The slow progression rate was configured as 1 divided by more than two years of progression. 
The fast progression rate was configured as 1 divided by less than two years of progression. The 
proportion of population who has fast progression rate was calibrated. This parameter also adds more 
structural specificity pertaining to TB disease. Lastly, the healthcare seeking behavior in population is the 
integrative recognition of symptoms, presentation to health facilities, compliance with treatment, and 
hence, the way of reducing disease spread. We did not calibrate more than these three parameters, to 
reduce the dimension of combined posterior distributions and accordingly technical burden.  
 
Initial range of parameter values prior to calibration was selected based on experts’ guidelines and 
literature review. These parameter values were varied within the initial range during the calibration. The 
calibration process was based on incremental mixture importance sampling (IMIS), based on specified 
likelihood function (normal distribution of equally weighted incidence and mortality time-series overall 
from 2000 to 2017) in analyzer. IMIS is a type of repeated simulation mechanism using the simulation-
produced parameters for subsequent simulations at the maximum posteriori estimates. (20) The joint 
posterior distribution of these three parameters values was estimated via IMIS. We changed the prior 
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range to the selected values for the three calibrating parameters. [Table 7] The baseline projection was 
made from a mean of several points resampled from the post-calibration parameter distribution.  
Interventions 
We used the baseline simulation model and simulated two counterfactual scenarios before and after the 
‘Treatment for All’ ART scale-up intervention, which was implemented in 2016. The main outcome was 
the projected TB incidence in 2035 with the two scenarios. The first counterfactual scenario was if the 
ART scale-up had not been made in 2016. We held the HIV testing and ART coverage rate constant since 
2013, the latest year we could estimate the rates based on the Botswana AIDS Impact Survey (BAIS) IV. 
The second counterfactual scenario was if the ART scale-up successfully increased the HIV testing and 
ART coverage rate to the UNAIDS’ 90-90-90 goal. The 90-90-90 goal is to test 90% of people living with 
HIV, 90% of tested HIV people taking ART, and 90% HIV people under ART suppressing the HIV viral load.  
(20) 
  
The HIV testing and ART coverage rates before the ART scale-up were estimated from the BAIS IV 
conducted in 2013. The question of “How many times have you been tested [for HIV] in the past 12 
months?” and “Are you currently taking ART?” were used, respectively. After applying the survey 
sampling weights, the proportion of people who have tested at least once and the proportion of people 
who were under ART among HIV positive individuals were estimated for the HIV testing and ART 
coverage rate, respectively. It produced 67% HIV testing rate and 44% ART coverage, which was used to 
represent the rates before the ART scale-up in 2016. The HIV testing and ART coverage rates after the 
ART scale-up were set at 90% and 90% * 90% = 81%, respectively. It is under the assumption that the 
ART scale-up would successfully increase the HIV testing and ART coverage rates as high as the UNAIDS’ 
90-90-90 goal by 2020.  
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The projected TB incidences in 2035 with the two scenarios were compared to the TB incidence from 
the baseline model. The incidences were also compared to the TB incidence in 2015 (356 cases per 
100,000), to evaluate the relative contribution of the ART scale-up intervention to the TB epidemic.  
 
Results 
To account for stochastic feature of the EMOD simulation, each intervention was simulated 20 times. At 
the baseline, the mean of simulated TB incidence in 2035 was 260.0 per 100,000. Simulations from the 
first and second scenario produced the mean of TB incidence in 2035; 350.9 and 255.6 per 100,000, 
respectively. Compared to the baseline, the ART scale-up intervention reduced the projected TB 
incidence in 2035 by further 2%. Without the intervention, the projected TB incidence in 2035 was 35% 
higher than the baseline. On the other hand, compared to the 2035 WHO’s global target goal, which is 
35.6 per 100,000 in Botswana (corresponding to 90% reduction from 356 per 100,000 of TB incidence in 
2015 in Botswana), the ART scale-up intervention reduced the TB incidence at 2035 by 22%. [Figure 5] 
 
Discussion 
We developed an individual-based model of TB transmission to evaluate the effect of the ART scale-up 
intervention on future trends (by 2035) in the incidence of TB in Botswana. By comparing the projection 
from the ART scale-up scenario to the projection from the baseline model, we estimated the degree to 
which the ART scale-up intervention further contributed to reduction in TB incidence.  When the ART 
scale-up increased the ART coverage rate as high as 81%, we could expect 2% further reduction 
compared to the baseline model, which had the current ART coverage rate or 72%. The ART scale-up 
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intervention also reduced further 22% by 2035 compared to the estimates in 201 – it was a limited 
impact given 90% reduction of the 2035 global target goal. 
 
Based on the calibration result, our model projection was estimated higher than the reference data, 
partially because the trend of TB incidence plateaued out in the projection. It may be affected by high 
ART coverage rate even before the ART scale-up was intervened. It also aligns with the current trend of 
slow reduction in TB incidence worldwide. Current global trend of decline in TB incidence rates is 
average 1.5% per year, whereas desired decline is 10% by 2025 and 17% per year to reach the 2035 
target. (21) High ART coverage going forward even in the scenario of no ART scale-up intervention and 
rapid increase in ART coverage after the intervention has been recognized in Botswana. (21) Regardless 
of the limited impact, the additional 30% reduction in TB incidence (compared to the prior and post ART 
intervention) is worth noting, given the current rate of 1.5% annual reduction in TB incidence globally 
and 6% in Botswana. (17,22)  
 
Different reduction trend back in 2000s and nowadays may imply that countries with lower burden of TB 
need to find a different approach. People who are currently on ART in Botswana will become older, have 
the weakened immune system as part of aging, and can develop TB by 2035. As other low TB burden 
countries currently target individuals at risk such as marginalized populations and concern reactivated 
TB or drug-resistant TB, (23) Botswana will need to incorporate other interventions than ART. In addition 
to the future interventions Botswana may consider, our model did not incorporate other current TB 
prevention strategies among HIV co-infected populations, such as ‘Three Is policy’. (24) Isoniazid 
preventive treatment (IPT), intensified case finding for active TB (ICF), and TB infection control (IC) are a 
key public health strategy to decrease the TB burden on HIV infected populations, especially in the high 
TB and HIV settings. (25) As previous studies showed the combination use of IPT on the top of expanding 
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ART had an additional impact on preventing TB risk, (26,27) and  IC and ICF measures improved the cost-
effectiveness, (25) our model may have overestimated the future TB incidence. 
 
Previous modeling studies estimating a population-level impact of ART scale-up on TB epidemic in other 
similar settings were aligned with our prediction; (27,28) however, the study targeted HIV infected 
individuals mainly, conducted before the ‘Treatment for All’ ART intervention, and included less country-
specific contextual settings. Across sub-Saharan Africa countries, ART rollout may reduce TB incidence 
but not for a long term because of increased life-time TB risk among survived HIV infected populations. 
(27) Although we did not observe fluctuation or peak in TB incidence trends, a stunted reduction in the 
long-term TB incidence may be explained by the impact of maintaining HIV infected individuals on ART. 
Another study modelled in nine African countries including Botswana showed more dedicated HIV 
testing frequency and immediate ART initiation reduced the TB risk among HIV infected individuals. (28) 
Immediate ART initiation was possible in our second scenario of ART intervention without regard to CD4 
counts. And since TB risk among HIV uninfected individuals may be affected by lower TB incidence 
among HIV infected individuals, the results from nine African countries can straighten up to our result of 
reduction in TB incidence overall at the country-level. 
 
Our study had limitations. We made scenarios only with the first two goals of UNAIDS’ 90-90-90. We did 
not take viral suppression into consideration. Due to lack of related empirical data, it was unavoidable; 
however, given that the HIV viral level was used as a proxy of HIV transmission in communities, (29) the 
predicted TB epidemic would be incomplete at some degree. Lack of reliable data is a pervasive 
challenge across the parameterizing steps in the mathematical modeling approach, especially in the 
resource-limited countries. (30) We have abstracted parameters’ values from the systematic and meta-
analytic research, or population-based survey data. Accordingly, many assumptions (e.g. the systematic 
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review results may fit to the Botswana setting even if the review did not include Botswana studies) 
behind the model parameters were made. Well-structured data from the centralized healthcare system 
and data from the representative survey would benefit the further modeling approach.  
 
To our knowledge, we developed the first model of TB transmission specifically fitted to the Botswana-
specific setting. Though there were evidences of the ART impact on TB from previous modeling studies, 
simulated long-term effects, such as incidence TB risk ratio in the future 20 to 30 years, are likely to vary 
depending on the particular epidemiologic context. (28) Besides, growing number of countries – more 
than 20 countries in sub-Saharan Africa last year, used a country-specific model as a routine TB policy 
making process. (30)  Given this situation, we expect our model will be highly applicable to a wide range 
of interventions specifically in Botswana, for example, to make efficient choices within limited 
resources, to evaluate the current TB control programs, and even expandable to conduct a cost-
effectiveness analysis.  
 
Our model and its results provide implications to other countries with high TB and HIV burden in 
addition to the Botswana setting. Botswana has been one of the highest TB and HIV burden countries. 
The government of Botswana highly committed to TB and HIV treatment programs. For example, as HIV 
testing is a key step in HIV prevention and care, (21) Botswana has utilized point-of-care HIV testing 
beyond the clinic- or facility-level to the community- and health program-level. (21) To reach all HIV-
infected individuals, it also put efforts to append innovative service delivery. (31) In addition, 
Botswana’s free, decentralized, and universal ART program in 2002 was the first attempt among all 
other African countries, (1) and the ‘Treatment for All’ ART intervention became a good example of 
controlling both TB and HIV epidemics. Our model well reflected these backgrounds of Botswana’s high 
burden of TB and its high commitment to reducing the burden. The model projection may bring lessons 
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to other sub-Saharan African countries with significant burden of TB and HIV regarding the importance 
of strong health system, public programs’ responsiveness to changes in disease epidemiology over time, 
and political and health structural environments. (21) 
 
In summary, we developed an individual-based model of TB transmission in Botswana, and estimated 
the projected TB incidence at 2035 and the degree to which the ART scale-up intervention contributed 
to the projection. The population-level universal ART intervention attributed to additional reduction in 
TB incidence, though its impact was limited to reach the 2035 global target goal. Further studies 
focusing on local transmission and a population at high risk for TB and HIV, such as communities with 
the low socioeconomic status and individuals immigrated from higher TB and HIV burden settings, may 
shed light on the limited impact of ART at the country-level. Modeling with expanded options of 
intervention other than the ART scale-up will also project more reliable TB burden estimates. 
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Tables 
 
Table 7. Key model input parameters 
Parameters Values  Data source 
 Prior 
range 
Post-
calibration 
 
Basic reproduction number* 3.65 – 7.30 5.48 Expert judgement 
Proportion of fast TB disease progressors (%) 5.0 – 10.0 7.6 Expert judgement 
Mean time to diagnosis from symptom (days) 30 – 365 150 Expert judgement 
Diagnostic (Smear microscopy) sensitivity Smear (+) Smear (-)   
HIV Negative 0.90** 0.61 
(32,33) 
HIV Positive (CD4<200) 0.90 0.65  
HIV Positive (CD4<250) 0.90 0.65  
HIV Positive (CD4<350) 0.90 0.65  
HIV Positive (CD4<500) 0.90 0.65 
HIV Positive (CD4>500) 0.90 0.65  
Diagnostic (GeneXpert) sensitivity Smear (+) Smear (-)   
HIV Negative 0.97 0.68 
(32,33) 
HIV Positive (CD4<200) 0.81 0.65 
HIV Positive (CD4<250) 0.81 0.65 
HIV Positive (CD4<350) 0.81 0.65 
HIV Positive (CD4<500) 0.97 0.68 
HIV Positive (CD4>500) 0.97 0.68 
Symptom-based and Chest X-ray sensitivity HIV (+) HIV (-)   
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0.94 0.85  (34) 
Treatment pathway drop-out (%)    
Prior to Directly Observed Therapies (DOTS) 0.25 
(35)(36) 
Posterior to DOTS 0.10 
Treatment outcome prior to DOTS (%) HIV (+) HIV (-)   
Duration (days) 180 180 
(15) 
Cure*** 0.60 0.60 
Relapse 0.20 0.20 
Death or failure**** 0.20 0.20 
Treatment outcome posterior to DOTS (%) HIV (+) HIV (-)  
Duration (days) 270 270 
(15) 
Cure  0.80 0.80 
Relapse 0.05 0.05 
Death or failure  0.15 0.15 
* Basic reproduction number per year when all individuals are susceptible under no effective 
interventions 
** Sensitivity of smear microscopy test on smear positive sputum ≈ 1.00 based on its definition, with a 
degree of variation due to smear test facilities, sputum sample condition, and so on.  
*** Cure include inactivation 
*** Other failures than death include reactivation and drug-resistance 
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Table 8. Other parameters configured in the TB and HIV simulation model. This parameter set is embedded in the Epidemiologic MODeling 
(EMOD) TB and HIV model and directly referenced from http://www.idmod.org/docs/tuberculosis/parameter-configuration.html. We present 
the only parameters that are used in our model. For example, parameters related to geography, environment, migration, sampling by 
subdistrict, multi-drug resistant TB, etc. are not considered a part of our model and not presented. 
Parameter Description Value 
TB natural history parameters 
TB_Fast_Progressor_Fraction_Child Fraction of under-age 15 who are designated “fast progressors” 5% 
TB_Fast_Progressor_Fraction_Adult Fraction of over-age 15 who are designated “fast progressors” 11% 
TB_Fast_Progressor_Rate Rate from latent TB to active presymptomatic TB for “fast progressors”  2.0 yr-1 
TB_Slow_Progressor_Rate Rate from latent TB to active presymptomatic TB for “slow progressors” 0.005  yr-1 
TB_Latent_Cure_Rate Rate from latent TB to uninfected by spontaneous cure 0 yr-1 
TB_Base_Infectivity_Presymptomatic R0 for active presymptomatic TB 7.0 x 10-3 d-1 
TB_Presymptomatic_Rate Rate from active presymptomatic TB to fully active TB 2.7 x 10-3 d-1 
TB_Presymptomatic_Cure_Rate Rate from active presymptomatic TB to uninfected by spontaneous cure 0 d-1 
TB_Base_Infectivity R0 for fully active TB 2.2 x 10-2 d-1 
TB_Active_Mortality_Rate Rate of mortality with active TB 4.1 x 10-4 d-1 
TB_Active_Cure_Rate Rate from active TB to uninfected by spontaneous cure 2.7 x 10-4 d-1 
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TB_Smear_Positive_Fraction_Child Fraction of under-age 15 who are designated smear-positive 2.5 x 10-1 
TB_Smear_Positive_Fraction_Adult Fraction of over-age 15 who are designated smear-positive 6.5 x 10-1 
TB_Smear_Negative_Infectious_Multiplier Multiplier for TB_Base_Infectivity for smear-negative 1.5 x 10-1 
TB_Smear_Negative_Mortality_Multiplier Multiplier for TB_Active_Mortality_Rate for smear-negative 1.5 x 10-1 
TB_Extrapulmonary_Fraction_Child Fraction of under-age 15 who are designated extrapulmonary 4.0 x 10-1 
TB_Extrapulmonary_Fraction_Adult Fraction of over-age 15 who are designated extrapulmonary 1.0 x 10-1 
TB_Extrapulmonary_Mortality_Multiplier Multiplier for TB_Active_Mortality_Rate for extrapulmonary 1.5 x 10-1 
TB_Enable_Exogenous Controls whether or not exogenous reinfection of latent TB can occur 1 
TB_Extrapulmonary_Fraction_Adult The fraction of active cases in adults (age 15 or over) that are 
extrapulmonary. Extrapulmonary individuals are considered non-
infectious 
0.1 
TB_Extrapulmonary_Fraction_Child The fraction of active cases in child (age under 15) that are 
extrapulmonary. Extrapulmonary individuals are considered non-
infectious 
0.4 
TB_Extrapulmonary_Mortality_Multiplier The scale factor for the mortality rate of active extrapulmonary 
individuals 
0.15 
72 
 
TB and CD4 activation 
CD4_Strata_Activation CD4 levels below which a modified slow progressor rate is used {3.0 x 10-2, 3.5 x 
102, 5.0 x 102, 2.0 x 
105} 
TB_CD4_Activation_Vector Slow progressor rate (i.e., transition rate from latent TB to active TB) for 
different CD4 levels 
{5.5 x 10-4 d-1, 3.0 x 
10-4 d-1, 1.0 x 10-4 d-
1, 1.4 x 10-5 d-1} 
TB_CD4_Infectiousness Multiplier on R0 for active TB in HIV-TB co-infected 6.0 x 10-1 
Infectivity and Transmission 
AIDS_Stage_Infectivity_Multiplier Applied to the length of time prior to an AIDS-related death 1 
ART_Reactivation_Factor Factor for ART reducing reactivation in HIV positives 1 
CoInfection_Mortality_Rate_Off_ART The daily rate of death in excess to TB when coinfected with HIV off ART 0.0003 
CoInfection_Mortality_Rate_On_ART The daily rate of death in excess to TB when coinfected with HIV on ART 0.0001 
TB_CD4_Infectiousness Relative multiplicative increase in TB infectiousness due to HIV 
positivity/CD4 decline 
{2.0, 1.5, 1.4, 1.3, 
1.2, 1.0, 0.5} 
73 
 
TB_CD4_Strata_Infectiousness_Susceptibility The CD4 strata defining increases and decreases in TB infectiousness and 
susceptibility 
{1E-09, 250, 300, 
350, 500, 2000, 
20000} 
TB_CD4_Susceptibility The relative increase in TB susceptibility due to HIV/CD4 decline {1, 1, 1, 1, 1, 1, 1} 
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Figures 
Figure 3. Model scheme 
 
TB; tuberculosis, HIV; human immunodeficiency virus, ART; antiretroviral therapy, and CXR; chest X-ray 
Individuals’ move from state (box) to state was tracked over time. It is regulated by the assigned rule based on individuals’ characteristics and 
the duration individuals stay at one state. The rule incorporates randomness. Presumptive TB individuals who start a healthcare seeking 
behavior are diagnosed by smear microscopy before 2016 and by GeneXpert after 2016, following the Botswana National TB Guideline. 
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Diagnosis results (e.g. depending on sensitivity and specificity) are determined by HIV infection status and smear positivity as well as individuals’ 
characteristics. HIV test is added to the model independently from TB test. HIV positive individuals are randomly given one of five different CD4 
cell counts – this model construction reflects the CD4 cell count-dependent TB disease progression and the updated ART eligibility guideline 
(that is based on the CD4 cell count over time). Individuals whose TB test is negative go through additional clinical diagnosis or chest X-ray. 
Individuals diagnosed as TB are linked to start or failed to link to treatment with different probabilities. TB treatment requires longer duration 
and has lower efficiency (e.g. lower cure rate and higher failure rate) and higher dropout rate before 2003, the year when the directly observed 
therapies (DOTs) were introduced. TB treatment requires shorter duration and has higher efficiency and lower dropout rate after 2003. 
Presumptive individuals, who are ruled out through the diagnosis steps and who drop out from the treatment cascade, go back to the healthcare 
seeking step. The same healthcare seeking rate is applied to the re-seeking rate. 
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Figure 4. Calibration results  
 
 
 
 
 
 
 
Left figure is the trend of tuberculosis disease mortality. Middle figure is the trend of the tuberculosis disease incidence. Black dots are the 
reference data (from 2000 to 2017) that are extracted from the World Health Organization database. Blue lines are the model estimations. Right 
figure is HIV prevalence and antiretroviral therapy coverage rate in the baseline model. Top line is the antiretroviral therapy (ART) coverage rate 
over time in Botswana. Bottom line is the HIV prevalence rate in overall population (not limited to adults aged over 15 years) over time in 
Botswana. Botswana introduced free and universal ART in 2002 for individuals with CD4 T-cell counts lower than 200 cells/mm3. It raised the 
CD4 threshold to 250 cells/mm3 in 2008, to 350 cells/mm3 in 2013, and, in accordance with the WHO’s “Treatment for All” strategy, to all PLHIV 
regardless of CD4 level in 2016. The ART coverage rate at 2017 is estimated 72% according to the 2018 UNAIDS report. It is reflected in the 
model as (c).  
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Figure 5. Projected TB incidence trends by 2035 from two counterfactual scenarios 
 
 
 
TB incidence in 
2015 (/100,000) 
TB incidence in 
2035 (/100,000) 
Reduction from 
the baseline 
Reduction 
from 2015 
Reference data 356 - - - 
Baseline model 
estimates 
358.5 260.0 - 20% 
Scenario 1 
Before “Treatment 
for all” ART 
intervention 
358.5 350.9 +35% +8% 
Scenario 2 
After “Treatment for 
all” ART intervention 
358.8 255.6 2% 22% 
 
The 2035 global target goal is a 90% reduction in TB incidence from the 2015 estimates. The black line is at 35.6 per 100,000. The purplie line is 
from the World Health Organization reference data, the green line is from the baseline estimates, the blue line is from the first counterfactual 
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scenario (without ART scale-up in 2016), and the red line is the second counterfactual scenario (with ART scale-up). The projected TB incidence 
with two scenarios are compared to the baselind model and to the 2015 estimate.  
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Chapter 4. Possible Transmission Mechanisms Associated with Mixed Mycobacterium Tuberculosis 
Infections in a High HIV-Prevalence Country 
Abstract 
Background 
Concurrent infection with multiple strains of M. tuberculosis complex (MTBC), referred to as mixed 
infection, challenges traditional clinical and epidemiologic paradigms. Our study explored possible 
transmission mechanisms associated with mixed infection in a population-based, molecular 
epidemiology study in Botswana — the KOPANYO study.  
Methods 
During 2012–2016, all registered tuberculosis (TB) patients in Gaborone and Ghanzi districts were 
eligible for enrollment. We considered mixed MTBC infection as multiple repeats of alleles at two or 
more loci within 24-locus MIRU-VNTR results in the baseline sputum culture. We compared MIRU-VNTR 
patterns of all MTBC strains to those of each of mixed infections to identify matched strains to each 
mixed infection. Matched strains were classified as genotypic-clustered if found in two or more patients, 
including the mixed infection patient; and non-clustered, if occurred only in the mixed infection patient. 
The spatiotemporal link was considered among TB patients, who held a mixed strain and its possible 
precursor strains, were also compared to supplement the possible transmission mechanism. 
Results  
Among 2137 TB patients, 1218 (57%) were HIV-infected. MIRU-VNTR detected 885 different strains, of 
which 37 (4.2%) were mixed infections. Twenty-three strains (62%) had patterns consistent with a 
combination of genotypic-clustered and non-clustered strains, 10 (27%) with multiple non-clustered 
strains, and 4 (11%) with multiple clustered strains. Among 37 patients, 22 (59%) were HIV-infected; 50 
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– 61% across the possible transmission patterns. Within the 300m neighborhood and within two-year 
gap of TB diagnosis date, one mixed infection patient identified spatiotemporal links with two other 
patients of possible precursor strains. 
Conclusions 
High proportion of mixed infections was attributable to a combination of clustered and non-clustered 
strains suggesting that both, recent transmission and reactivation led to mixed infections. Public health 
interventions that reduce multiple exposures to TB may also reduce the prevalence of mixed TB 
infections.  
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Introduction 
Concurrent infection with multiple strains of M. tuberculosis complex (MTBC) is referred to as mixed 
MTBC infection. The first case of mixed MTBC infection was reported in the mid 1970s, but it was not 
until recently that advanced molecular tools identified mixed MTBC infection cases more frequently 
than initially expected. (1, 2) Since then, mixed MTBC infections have been associated with poor 
treatment outcomes, (1, 3) including multi-drug resistant TB (MDR-TB). (2, 3) Mixed infection also 
contributed to the discovery that exogenous reinfection was attributed to a big portion of TB incident 
cases, implying incomplete protection from a primary infection against subsequent MTBC infections. (4, 
5)   
 
The mechanisms by which mixed infections occur and its population-level impact have only been 
explored hypothetically through simulation models. (4, 6) By definition, mixed MTBC infections require 
the patient to be infected with two or more strains. However, multiple potential mechanism and timing 
of MTBC infections may be envisioned. Infections with multiple MTBC strains may occur after the 
simultaneous transmission of multiple strains during a single transmission episode (the index case 
simultaneously transmitting multiple strains) or by sequential infections with MTBC strains at different 
times (superinfection). (5) In the latter, depending on the timing of the discrete episodes, mixed 
infections can occur through several general scenarios: 1) simultaneous reactivation of 2 or more old 
infections (occurred at least 2 years prior to the diagnosis of active disease with mixed MTBC infections); 
2) a recent infection leading to the reactivation of an old one; and, 3) rapid progression of 2 or more 
recently acquired strains.  However, without empirical evidence, it is uncertain how much a force of 
infection in community may drive superinfection, if mixed strains can be transmitted simultaneously, 
how far tuberculous reactivity contributes to transmission due to reinfection, and so on. Research on a 
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transmission mechanism will help understanding TB disease dynamics and assessing current TB control 
interventions. (7) 
 
The overall goal for the study was to explore the possible transmission mechanisms leading to mixed 
MTBC infections. First, the possible transmission mechanisms associated with mixed infections were 
identified through genotypic data. Genotyping MTBC strains and identifying genotype clusters have 
been used as a proxy for recent transmission and used in TB outbreak investigation and surveillance. (8, 
9) We expanded the genotypic-level clusters spatiotemporal to provide epidemiologic plausibility in a 
transmission chain. We looked at the possible transmission mechanisms stratified by HIV status to 
explore different risk of mixed infection and different transmission and disease patterns. (4, 5, 10)  
 
Methods 
Study setting 
We used a population-based, molecular epidemiology study in Botswana —the KOPANYO study. The 
study recruited and enrolled newly diagnosed TB patients during 2012 – 2016. Further information 
regarding the KOPANYO study design and methods can be found elsewhere. (11) Briefly, all participants 
were recruited from TB and HIV clinics and their close contacts were also identified through the active 
contact investigation. Their demographic, clinical, and residential geocode information and sputum for 
Mycobacterium tuberculosis (MTB) isolates were collected.  
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MIRU-VNTR and definition of mixed infection 
The genotyping method 24-locus Mycobacterial Interspersed Repetitive Unit-Variable Number Tandem 
Repeat (MIRU-VNTR) was used to identify mixed infection. The number of repeats at 24 loci, which have 
unique repeat sequences, were counted. (5) Mixed infection was defined as MTB having multiple 
repeats of alleles at two or more loci, based on MIRU-VNTR patterns. Possible mixed infection was 
defined as MTB with multiple repeats of alleles at one locus, as such infections may indicate mixed 
infections or clonal heterogeneity within the host.  Single infection was defined as MTB with a single 
allele at all 24 loci.  
Definition of genotypic cluster 
To identify MTB strains that were associated with mixed infection strains, MIRU-VNTR patterns for all 
MTB strains were compared to each of the mixed strains. We identified MTB strains which had MIRU-
VNTR patterns that clustered with a possible precursor of the mixed strains. For single strain MTB 
infections, when alleles at all 24 loci were exactly matched to a mixed strain, they were considered to be 
a genotypic cluster. For possible mixed or mixed strains, when alleles at all 24 loci included exactly 
matched tandem number(s) but did not contain non-matched tandem number(s), they were considered 
to be part of a genotypic cluster. For example, if the 22nd locus had tandem numbers 2 and 4 in a mixed 
strain, the matched MTB strains should include 2, 4, or both at the same locus, but they should not have 
any other numbers than 2 and 4. [Figure 6] Mixed strains with (a) missing locus (or loci) were excluded 
in comparison. (A) Missing locus (loci) of compared MTB strains were not included in the analysis of 
genotypic clustering. 
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Combination of clustering among mixed infections 
Based on the genotypic cluster analysis described above, each mixed infections case was defined as into 
three categories of clustering. By definition, the matched strains in subset data were all genotypic-
clustered strains. When these strains may explain all alleles of mixed strain, the mixed infection was 
classified into the first transmission mechanism, multiple clustered infections. When the matched 
strains may explain a part of mixed strain, the mixed infection was classified into the second mechanism, 
a combination of clustered and non-clustered infections. When a mixed strain had an empty subset 
data, implying no MTB strains were matched to, the mixed infection was classified into the third 
mechanism, multiple non-clustered infections.   
 
Definition of spatiotemporal clusters 
We added spatiotemporal data to support epidemiologic plausibility for genotypic clusters. First, 
residential address data collected at study enrollment was used as evidence of clustered infections 
within households and neighborhoods. The size of household was first defined within 50m radius from a 
location of mixed infection as the center, accounting for approximate diagonal distance of each 
household. There is no standardized definition of neighborhood size. We increased the size of radius 
until we found at least one epidemiologic link, which was 150m radius from a location of mixed infection 
as the center. We counted how many TB patients met the clustered infection criteria at genotypic-level 
and spatially. Once the genotypic and spatial cluster was confirmed, their TB diagnosis date or first TB 
treatment initiation date was compared to supplement the temporal association. Given two-year 
latency period of TB, we confirmed the temporal connection when the TB diagnosis date or first TB 
treatment initiation date was overlapped within two years.  
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Sensitivity Analysis 
We used a different definition of genotypic clustering, by allowing MTB strains which MIRU-VNTR 
pattern to have one locus difference from mixed infection strains. A pair of one mixed strain and its 
completely matched MTB strains or partially matched MTB strains (which MIRU-VNTR pattern was 
different at one locus) were in a transmission link at genotypic level in the sensitivity analysis.  
  
Statistical Analyses 
Main analyses were done at the genotype level. The prevalence of each MTB strain was estimated in the 
study districts, and the probability of a more frequent strain associated with the mixed strain 
transmission was compared. For each mixed strain, a user-defined loop function compared tandem 
numbers from the first locus to 24th locus with all other MTB strains one locus by one locus. When there 
were discrepancies between tandem numbers at a locus, the locus was marked ‘flagged’. The number of 
flags was counted after comparing 24 loci. If all numbers were matched the number of flags was 0, 
whereas if none of them were matched the number was 24. The number of flags was used to detect the 
degree to which the MIRU-VNTR pattern were matched to that of the mixed strain. In the end of the 
loop function, it created subset data with all MTB strains by descending order of the number of exactly 
matched loci (from 0 for exactly matched at all 24 loci), for each of the mixed strains. The MTB genotype 
data was analyzed by SAS 9.4. (SAS Institute Inc. Cary, NC, USA ©2014)      
 
We also conducted analyses at the patient level. This included study districts where a patient with a 
specific MTB strain identified, prevalence of mixed infection cases, and HIV infection. The TB patients 
were mapped based on their primary residential address, using Geographic data was analyzed by 
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ArcGIS. (ESRI 2011. ArcGIS Desktop: Release 10. Redlands, CA: Environmental Systems Research 
Institute) Analyses were also stratified by HIV status.  
  
Results 
Among 2137 patients whose MIRU-VNTR genotyping data was available from the KOPANYO study 
participants, 1218 patients were HIV positive (57%). [Table 9] Both in HIV positive and negative groups, 
majority of them had a single strain MTB (94%). The total number of different MTB strains detected in 
the study population was 862. More diverse MTB strains were detected among HIV positive (570 of 862 
strains, 66%) compared to HIV negative (453 of 862 strains, 53%) TB cases. 
 
After excluding patients who were infected with MTB strains of (a) missing allele(s), there were 2,051 
patients left. A total of 37 mixed infection cases (1.8%) or 131 mixed and possible mixed infection cases 
(6.4%) were found. Our data suggest that 23 mixed infection cases developed through a combination of 
genotypic-clustered and non-clustered strains, 4 were developed from genotypic-clustered strains, and 
10 developed from concurrent infections with non-clustered strains. Overall, genotypic-clustered strains 
were associated with 73% (27 of 37) mixed infection cases. Higher proportion of mixed infection cases 
were HIV positive (59%). [Table 10] The comparison between the mixed infection strains and their 
matched strains are presented in [Table 11 – 13].  
 
After excluding cases whose geographic location information was missing, 449 patients’ (37 patients 
with the mixed strains and 412 patients with clustered strains) geographical clusters were explored. 
[Figure 7] Based on our definition of genotypic non-clustered strain, which was no matched strains 
identified in the community, the spatial link was identified only between the mixed infections and 
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genotypic-clustered strains. We did not find a spatial connection within the 50m radius, and one spatial 
connection within the 150m radius. [Figure 8] Two patients with matched MTB strains were temporally 
associated with the mixed strain and lived within a 150m radius; one patient was diagnosed as TB three 
months ahead of the mixed strain patient and may play a role as a precursor. The other patient was 
diagnosed two years later than the mixed strain patient. [Table 14] Both patients with the matched MTB 
strain had the same MIRU-VNTR pattern, and it was the second most prevalent strain in the study sites 
(MIRU ID = 382 in Table 11 and Table 14).  
 
After we allowed MTB strains to have MIRU-VNTR patterns differ by one locus, 7 mixed infection cases 
had updated transmission mechanism. Overall, there was no change in that the highest proportion 
(N=19, 51%) of mixed infection cases occurred through a mixture of genotype-clustered and non-
clustered strains. The second highest proportion (N=10, 27%) of mixed infection cases were a mixture of 
multiple genotype-clustered strains. 
 
Discussion 
In our study, the highest proportion of mixed infection cases was composed of strains both from 
clustered and non-clustered infections, rather than clustered infections dominantly. Molecular methods 
or genotyping MTB strains have been used to investigate the TB outbreaks and used as a proxy of recent 
transmission. (8, 9) From our molecular genotyping data, we also hypothesized that clustered infections 
may represent recent transmission and non-clustered infections may represent reactivation from 
remote infections. This means that, more than 60% of mixed infection cases may have occurred through 
both recent transmission and reactivation from remote infection. This mechanism explained higher 
proportion of mixed infection transmission than other two mechanisms of multiple recent transmissions 
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or multiple reactivations. This finding was different from our expectation that most mixed infections 
were attributable to a recent transmission chain. In high TB endemic settings, current TB control and 
prevention methods have mainly focused on halting recent transmission and detecting and treating 
active cases. (12) Interventions to interrupt the transmission link will reduce the opportunities of 
exogenous re-infection and hence mixed infection. (5) However, our results may imply the significance 
of treating for latent TB infection in high TB burden settings, not only in low burden countries where 
remote infection was known to contribute substantially to TB burden. (13) Remote infection or latent TB 
infection is rather considered a problem in high-income or low TB burden countries, (12, 13) but it 
should be well understood that its reactivation aroused by ongoing transmissible TB will bring in more 
complicated TB epidemic in high TB burden settings. (1) Additional studies will be needed to better 
understand this phenomenon. 
 
In this study, we applied a strict definition to the mixed MTB infection, and the estimated prevalence 
was 1.8%. In the sensitivity analysis with the new definition of considering the possible mixed infections 
as mixed infection, the estimated prevalence was 6.4%. Our estimation was generally lower than 
previous reports, which were up to 56%. (1)  For this comparison, we referenced the previous studies, 
which used MIRU-VNTR from other high TB and HIV settings, as the estimation of mixed infection 
burden differs depending on a specific genotyping method and the level of MTB transmission in a given 
population. (5, 6, 14) Despite similar settings in comparison, this big discrepancy may be explained by 
the population-based data we used for our estimation, as the previous studies were conducted among 
particular settings such as small study samples, majority HIV positive patients, previously TB treated 
patients, autopsies, drug resistant cases, and in hospitals. (5, 15) Notably, we only captured the lower 
boundary of the estimation in that we excluded the strains with missing loci and followed the strict rule 
of matched alleles at all 24 loci. Hence, estimated 1.8 – 6.4% may represent the burden of mixed 
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infection in general population in high TB burden settings, even though this estimation was also not free 
from underestimated as like other previous estimations, compared to the modeling study which tried to 
capture minority MTB strains and overcome the limited diagnostic sensitivity issues. (16) 
 
In our study, about three quarters of mixed infection cases were associated with recent ongoing 
transmission MTB strains, implying that mixed infection may be affected by the force of infection in 
communities. (4, 6) We estimated the prevalence of each MTB strain in the study sites as a proxy 
measure of force of infection in communities. As opposed to our expectation, we found two dominant 
MTB strains appeared rarely in the mixed infection transmission chain. Such features may be explained 
by that less transmissible strains may outcompete other strains as long-term persistency within host 
played a more important role than outnumber reproductive power, according to the MTB ecologic and 
population-level mixed infection impact modeling study. (6) In addition, as some specific MTB lineages 
(e.g. Beijing) were likely to occur mixed infection, (6) future research using Whole Genome Sequencing 
may provide further insights. 
 
Our data presented that none of mixed strains were shared by more than one patient. Despite the 
limited knowledge on MTB strains’ ecology and diversity, rare simultaneous transmission may imply that 
only one outcompeting MTB strain likely contributed to the transmission. The abilities of MTB strains to 
compete within and between hosts were simulated through mathematical model studies previously. (6) 
However, before expanding further interpretation, it should be considered that minority strains might 
be missed during the specimen collection or genotyping. (4, 16)  
 
We also explored host characteristics that may contribute to different transmission mechanisms and 
found that more than half of mixed infection cases and genotypic matched cases were co-infected with 
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HIV. As 60% of HIV positive mixed infection cases were consistent with multiple ongoing transmission 
strains and more diverse MTB strains were found among HIV positive study population, people with HIV-
associated impaired immune system may be more susceptible to reinfection from transmissible MTB 
strains. Further comprehensive assessment with CD4 count data and analysis stratified by CD4 count 
may help to establish stronger associations between HIV infection and risk of mixed MTB infection. (17) 
We added the spatiotemporal information to the identified possible genotype transmission, using 
residential address and hospital admission or first TB treatment initiation date as a proxy of TB diagnosis 
date. Our neighborhood definition was based on the physical distance, which is a limited indicator for 
social mixing pattern. In high incidence settings with strong spatial link but no genotype association 
aligned with other previous findings that majority of known contacts or household were not in the same 
transmission chain. (18-20) The authors of that study suggest expanding the spatial link range to 
communities. As we explored broader spaces than traditional household studies, no genotype 
association from our study may conform to recently raised questions on the significant degree of within-
host MTB heterogeneity. (21, 22) To capture transmission chains, a possibility of within-host MTB 
diversion should be considered when inferring the TB transmission mechanism. (21, 22) Uncertain wide 
range of latency period of MTB antigens was a big barrier in incorporating temporal data, though our 
analysis followed the recent advice of average two-year latency period of MTB. (12, 13, 21)  
 
A common limitation in all TB transmission research involving molecular epidemiology is the inherent 
limitations of molecular typing methods that may lead to difficulties in interpretation. In this study, we 
used the 24-loci MIRU-VNTR method, which was considered the gold standard at the time of the study 
among existing molecular typing tools, (23) but has a problem with distinguishing mixed infections from 
clonal heterogeneity. (4, 15) We defined and analyzed possible mixed infection and mixed infection 
separately, however, as an attempt to differentiate more certain mixed infection cases from within-host 
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heterogeneity. Another limitation involves misclassification bias due to the detection sensitivity. (17) 
Whether or not MTB strains were matched to the mixed strains depended on the sensitivity of the 
genotyping methods. The 24-loci MIRU-VNTR method is relatively sensitive and has high discriminatory 
power; however, this method only looked at a part of MTB genome. (1) Hence, when there were 
randomly missing tandem repeats on a locus, the power was decreased proportionally to the number of 
loci. (7) The prevalence of each MTB strains was also dependent on the degree to which we identified 
different types of MTB strains in the study sites. Not all sputum samples could produce MTB isolates nor 
genotype results. (19) Similarly, whether a MTB strain was ongoing transmissible or unique reactivated 
heavily relied on identifiable strains in the study site. As genotyping methods were done on sputum 
samples from active TB patients, not only quality of sample collection and treatment may affect the 
mixed infection results, but also there is a possibility that minority strains at the time of sample 
collection may be undetected. (4) This may result in missed transmission link; (12, 21) however, to 
increase the case finding rate and complement the sensitivity of diagnostic tools, we used the 
population-based data recruiting TB patients through both passive case finding and active case finding. 
The transmission link may have been further underestimated, as reinfections with the same pattern of 
MTB were not identified due to a methodological limitation of the MIRU-VNTR, (10) and extra-
pulmonary TB cases especially those with immunodeficiency were not captured based on the study 
protocol. This may be an important limitation as extra-pulmonary samples provided evidence of high 
frequency of mixed TB infections. (4, 5) 
 
Acknowledging the inherent limitations of applying molecular epidemiology and special caution on 
interpreting genotype data, our study was the first study to suppose the hypotheses of mixed infection 
transmission mechanisms, utilizing the population-based TB patients’ cohort data. We recommend 
future studies investigate molecular profiles of MTB strains with repeated sampling isolates and with 
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combined different sampling and genotyping strategies, to thoroughly capture the possibly missed 
transmission link.   
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Tables 
Table 9. Characteristics of study population (N=2137) 
  
HIV Positive HIV Negative HIV unknown 
  
N (%) N (%) N (%) 
  
1130 (53) 948 (44) 59 (3) 
Age * 
 
36.9 (10) 32.5 (16) 33.5 (14) 
Gender 
     
  
 
Male 558 (49) 584 (62) 43 (73) 
 
Female 572 (51) 364 (38) 16 (27) 
Study Site 
    
  
 
Gaborone 779 (69) 508 (54) 46 (78) 
 
Ghanzi 123 (11) 248 (26) 8 (14) 
 
Other Botswana 57 (5) 41 (4) 2 (3) 
 
Unknown 171 (15) 151 (16) 3 (5) 
Previous TB Hisotry 
    
  
 
Yes 227 (20%) 150 (16%) 11 (19) 
 
No 903 (80%) 798 (84%) 48 (81) 
Mixed infection** 
    
  
 
Mixed Infection 20 (54) 15 (41) 2 (5) 
 
Possible Mixed Infection 55 (59) 36 (38) 3 (3) 
 
Single Infection 1000 (53) 868 (44) 52 (3) 
Number of different strains *** 570 (66) 453 (53) 50 (6) 
* mean (standard deviation) 
** Row percentage after excluding patients with MTB strains of missing alleles (N=86) 
96 
 
** Total number of different MTB strains = 862 
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Table 10. Characteristics of patients with mixed tuberculosis infection (N = 37) 
  
N (%) 
Study Site 
   
 
Gaborone 20 (54) 
 
Ghanzi 7 (19) 
 
Other Botswana 3 (8) 
 
Unknown 7 (19) 
HIV Infection 
   
 
Positive 20 (54) 
 
Negative 15 (41) 
 Unknown 2 (5) 
Transmission Mechanism 
   
 
Ongoing + Ongoing 4 (11%) 
 
Ongoing + Reactivated 23 (62%) 
 
Reactivated + Reactivated 10 (27%) 
HIV Infection  
* Transmission Mechanism 
 Positive Negative 
 
Ongoing + Ongoing 1 (5%) 2 (13%) 
 
Ongoing + Reactivated 12 (60%) 10 (67%) 
 
Reactivated + Reactivated 7 (35%) 3 (20%) 
MTB, Mycobacterium Tuberculosis, Ongoing; ongoing transmission strains 
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Table 11. Transmission Mechanism of Mixed Tuberculosis Infection I. Ongoing clustered strains + Unique reactivated strains (N = 23) 
Mix
ed 
Infe
ctio
n 
MIR
UID 
Asso
ciate
d 
Strai
n 
MIRU
ID 
v_
_1
54 
v_
_4
24 
v_
_5
77 
v_
_5
80 
v_
_8
02 
v_
_9
60 
v__
164
4 
v__
195
5 
v__
205
9 
v__
216
5 
v__
234
7 
v__
240
1 
v__
246
1 
v__
253
1 
v__
268
7 
v__
299
6 
v__
300
7 
v__
317
1 
v__
319
2 
v__
369
0 
v__
405
2 
v__
415
6 
v__
434
8 
v__
216
3b 
Freq
uenc
y 
840   2 1+
2 
3+
4 
2 1+
3 
3+
5 
3 2+3 2 3 2+4 2+3 2 6 1 5 3 3 3 3+5 5+7 2+3 2 4+5 1 
 
1052 2 2+
4 
3+
4 
2 3 4+
5 
3 3+4 2 2+3 2+4 2+3 2 3+6 1 5 3 1+3 3 1+3 7 2+3 2 4 1 
 
X1 
 
1 
  
1 3 
 
2 
           
5 5 
  
5 . 
851   2 2+
4 
4 2 3+
4 
3 1+3 2+5 2 2+3 4 2+4 2 5 1 4+7 3+5 3 3+5 3 5+8 2 2+3 2+5 1 
 
524 2 4 4 2 3 3 3 5 2 3 4 4 2 5 1 7 3 3 5 3 8 2 3 5 6  
X2 
 
2 
  
4 
 
1 2 
 
2 
 
2 
   
4 5 
 
3 
 
5 
 
2 2 . 
884   2 2 3 2 3 4+
5 
3 2+3 2 3 2 3 2 3+5 1 5 3 3 3 3 8 3 2 3+4 1 
 
124 2 2 3 2 3 5 3 2 2 3 2 3 2 3 1 5 3 3 3 3 8 3 2 4 2  
657 2 2 3 2 3 5 3 2 2 3 2 3 2 3 1 5 3 3 3 3 8 3 2 4 6  
893 2 2 3 2 3 5 3 2 2 3 2 3 2 3 1 5 3 3 3 3 8 3 2 3+5 1  
X3 
     
4 
 
3 
     
5 
          
. 
830   1+
2 
2 4 2 4 3 1 2 2 3 4 1+2 2 5 1 5 3 3 2+3 1 4 2 2 2 1 
 
209 2 2 4 2 4 3 1 2 2 3 4 2 2 5 1 5 3 3 3 1 4 2 2 2 14  
X4 1 
          
1 
      
2 
     
. 
860   2 2+
3 
5 2 2 3 4 2 2 2 4 2 2 5 1 5 3 3 3 1 3+5 2 2 3 1 
 
246 2 2 5 2 2 3 4 2 2 2 4 2 2 5 1 5 3 3 3 1 5 2 2 3 2  
681 2 2 5 2 2 3 4 2 2 2 4 2 2 5 1 5 3 3 3 1 5 2 2 3 4  
X5 
 
3 
                  
3 
   
. 
841   2 3+
5 
3+
4 
2 1+
3 
4 3 2 1 2+3 1+4 4 2+3 5 0+1 3+6 3 2 2 2 8 3 2 3+4 1 
 
274 2 3 4 2 1 4 3 2 1 3 4 4 3 5 1 6 3 2 2 2 8 3 2 4 15  
X6 
 
5 3 
 
3 
    
2 1 
 
2 
 
0 3 
       
3 . 
937   2 3 3+
4 
2+
3 
2+
3 
3+
5 
3 1+2 2 3+4 2+4 2 2 3+5 1 5 3 2+3 3 3 8+9 2+3 2 3+5 1 
 
838 2 3+
4 
3+
4 
2+
3 
3+
4 
3+
4 
3 1+3 2 3+4 4 2+4 2 5 1 5 3 2+3 3 3 8+9 2+3 2 3+4 1 
 
949 2 3 4 3 2 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 3 1  
X7 
     
5 
 
2 
  
2 
  
3 
         
5 . 
912   2 2 4 2 1 3 3 2 2 3 4 2 2 6 1 5+7 3 3 3 5 3+4 2 2 4 1  
181 2 2 4 2 1 3 3 2 2 3 4 2 2 6 1 5 3 3 3 5 4 2 2 4 7  
852 2 2+
4 
4 2 1 3+
4 
1+3 1+2 1+2 2+3 4 1+2 2 6 1 4+5 3 3 2+3 2+5 4+6 2 2 2+4 1 
 
X8 
               
7 
    
3 
   
. 
100
6 
  2 4 4 2 3 3+
4 
3 4 2 2+3 4 2+4 2 5+6 1 5+7 3 1+3 3+5 1 7+8 2 2+3 4+5 1 
 
517 2 4 4 2 3 3 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 2  
558 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 40  
727 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 1 
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855 2 3+
4 
4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 1 
 
1012 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 4+5 3 1 3 1 7 2 2 4 1  
1017 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 8 2 2 4 1  
1052 2 2+
4 
3+
4 
2 3 4+
5 
3 3+4 2 2+3 2+4 2+3 2 3+6 1 5 3 1+3 3 1+3 7 2+3 2 4 1 
 
X9 
           
4 
 
5 
 
7 
  
5 
   
3 5 . 
868   2 2 2+
4 
2 3+
4 
3 1+3 2 2 2 4 2 3 5+6 1+2 2+5 3 3 3+5 3 3+5 1+2 1+2 2+3 1 
 
206 2 2 4 2 4 3 1 2 2 2 4 2 3 5 1 5 3 3 3 3 5 2 2 2 22  
674 2 2 4 2 4 3 1 2 2 2 4 2 3 5 1 5 3 3 3 3 5 2 2 2 3  
X10 
  
2 
 
3 
 
3 
      
6 2 2 
  
5 
 
3 1 1 3 . 
852   2 2+
4 
4 2 1 3+
4 
1+3 1+2 1+2 2+3 4 1+2 2 6 1 4+5 3 3 2+3 2+5 4+6 2 2 2+4 1 
 
181 2 2 4 2 1 3 3 2 2 3 4 2 2 6 1 5 3 3 3 5 4 2 2 4 7  
912 2 2 4 2 1 3 3 2 2 3 4 2 2 6 1 5+7 3 3 3 5 3+4 2 2 4 1  
X11 
 
4 
   
4 1 1 1 2 
 
1 
   
4 
  
2 2 6 
  
2 . 
843   2 2+
4 
2+
3 
2 3 5+
6 
3 3 2 3+4 4 4 2 5 1 5 3 3 3+5 3 7 3+4 2+3 2+5 1 
 
896 2 2 3 2 3 5 3 3 2 3 4 4 2 5 1 5 3 3 3 3 7 3 2 5 2  
X12 
 
4 2 
  
6 
   
4 
        
5 
  
4 3 2 . 
848   2 1+
4 
4 2+
3 
1+
4 
3 1 1+3 2 1+4 4 1 1+2 4+5 1 5 2+3 2+5 3 2 9 2 2 4 1 
 
428 2 4 4 2 1 3 1 3 2 1 4 1 1 4 1 5 2 5 3 2 9 2 2 4 1  
429 2 4 4 2 1 3 1 3 2 1 4 1 1 4 1 5 3 5 3 2 9 2 2 4 2  
X13 
 
1 
 
3 4 
  
1 
 
4 
  
2 5 
   
2 
      
. 
976   2 4 3 2 1+
4 
4 1+3 3 2 3 4 1+4 2 5 1 2 3 3 3 4 8 3 2 3 1 
 
399 2 4 3 2 4 4 3 3 2 3 4 4 2 5 1 2 3 3 3 4 8 3 2 3 6  
699 2 4 3 2 4 4 3 3 2 3 4 4 2 5 1 2 3 3 3 4 8 3 2 3 1  
X14 
    
1 
 
1 
    
1 
            
. 
942   2 3 4 2 1+
3 
2 3 2 2 2 4 1+2 1+2 5 1 5 3 3 3 2+4 6 2 2 2 1 
 
276 2 3 4 2 3 2 3 2 2 2 4 2 2 5 1 5 3 3 3 4 6 2 2 2 1  
X15 
    
1 
      
1 1 
      
2 
    
. 
837   2 3+
4 
3+
4 
2+
3 
4+
5 
3+
4 
3 1+3 2 2+4 4 2+4 2 5 1 5 3 2+3 2+3 3+4 7+8 3 2 3+4 1 
 
691 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 7 3 2 4 1  
838 2 3+
4 
3+
4 
2+
3 
3+
4 
3+
4 
3 1+3 2 3+4 4 2+4 2 5 1 5 3 2+3 3 3 8+9 2+3 2 3+4 1 
 
X16 
    
5 
    
2 
        
2 4 
    
. 
986   2 4 3 2 4 4 3 3 2 3 4 4 2 5 1 5 3 2 2 4+6 5+8 3 2 3 1  
404 2 4 3 2 4 4 3 3 2 3 4 4 2 5 1 5 3 2 2 4 8 3 2 3 1  
X17 
                   
6 5 
   
. 
846   2 3+
4 
3 2 4 4 3 3 2 3 4 4 2 5 1 3+5 3 3 3 6 8 3 2 3 1 
 
415 2 4 3 2 4 4 3 3 2 3 4 4 2 5 1 5 3 3 3 6 8 3 2 3 2  
X18 
 
3 
             
3 
        
. 
842   2 2+
3 
3+
4 
2 1 3 3 2 2 3 4 2 2 6 1 4 3 3 3 5 4 1+2 2 5 1 
 
178 2 2 4 2 1 3 3 2 2 3 4 2 2 6 1 4 3 3 3 5 4 2 2 5 8  
670 2 2 4 2 1 3 3 2 2 3 4 2 2 6 1 4 3 3 3 5 4 2 2 5 1  
X19 
 
3 3 
                  
1 
  
. 
849   2 2+
3 
4 1+
3 
1 3 3 1+2 2 3+4 4 2 2 5+6 1 5 3 2+3 3 3+5 4 2 2 5 1 
100 
 
 
162 2 2 4 1 1 3 3 2 2 3 4 2 2 6 1 5 3 3 3 5 4 2 2 5 1  
X20 
 
3 
 
3 
   
1 
 
4 
   
5 
   
2 
 
3 
    
. 
105
1 
  2 2+
3 
3+
4 
2+
3 
3+
4 
3 3 1+3 2 3+4 2+4 2+3 2 3+5 1 4+5 3 2+3 3 3 7 2 2 3 1 
 
316 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 7 2 2 3 2  
690 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 7 2 2 3 1  
X21 
 
2 3 2 3 
  
3 
 
3 2 3 
 
3 
 
4 
 
3 
      
. 
105
3 
  2 1+
4 
4 2 1 3 1 3 2 2 4+5 1 1+2 6 1 5 2 3+5 3 2 4+9 2 2 4 1 
 
445 2 4 4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 5 3 2 4 2 2 4 1  
453 2 4 4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 5 3 2 9 2 2 4 8  
713 2 4 4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 5 3 2 9 2 2 4 30  
993 2 4 4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 5 3 2 8+9 2 2 4 1  
1054 2 1+
4 
4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 3+5 3 2 4 2 2 4 1 
 
1090 2 4 4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 5 3 2 9+a 2 2 4 1  
X22 
          
5 
 
2 
           
. 
107
3 
  2 2 3 2 3 5 3 3 2 2+3 2 3 2 3 1 5 3 3 3 3 6+7 3 2 3 1 
 
660 2 2 3 2 3 5 3 3 2 3 2 3 2 3 1 5 3 3 3 3 7 3 2 3 2  
895 2 2 3 2 3 5 3 3 2 3 2 3 2 3 1 5 3 3 3 3 7 3 2 3 1  
1074 2 2 3 2 3 5 3 3 2 3 2 3 2 3 1 5 1+3 3 3 3 7 3 2 3 1  
X23 
         
2 
          
6 
   
. 
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Table 12. Transmission Mechanism of Mixed Tuberculosis Infection I. Ongoing clustered strains + Ongoing clustered strains (N = 4) 
Mix
ed 
Infe
ctio
n 
MIR
UID 
Asso
ciate
d 
Strai
n 
MIRU
ID 
v_
_1
54 
v_
_4
24 
v_
_5
77 
v_
_5
80 
v_
_8
02 
v_
_9
60 
v__
164
4 
v__
195
5 
v__
205
9 
v__
216
5 
v__
234
7 
v__
240
1 
v__
246
1 
v__
253
1 
v__
268
7 
v__
299
6 
v__
300
7 
v__
317
1 
v__
319
2 
v__
369
0 
v__
405
2 
v__
415
6 
v__
434
8 
v__
216
3b 
Freq
uenc
y 
838  2 
3+
4 
3+
4 
2+
3 
3+
4 
3+
4 
3 1+3 2 3+4 4 2+4 2 5 1 5 3 2+3 3 3 8+9 2+3 2 3+4 1 
 260 2 3 3 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 4 1 
 282 2 3 4 2 4 3 3 1 2 3 4 2 2 5 1 5 3 2 3 3 8 2 2 4 1 
 288 2 3 4 3 3 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 4 1 
 318 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 8 2 2 3 4 
 319 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 8 2 2 4 12 
 320 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 3 3 
 321 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 4 21 
 346 2 3 4 3 4 4 3 1 2 4 4 2 2 5 1 5 3 2 3 3 8 2 2 4 1 
 374 2 4 3 2 3 3 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 4 
 379 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 2 2 3 1 
 382 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 89 
 406 2 4 3 2 4 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 1 
 692 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 8 2 2 3 2 
 693 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 8 2 2 4 3 
 694 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 4 2 
 825 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 3 
 837 2 
3+
4 
3+
4 
2+
3 
4+
5 
3+
4 
3 1+3 2 2+4 4 2+4 2 5 1 5 3 2+3 2+3 3+4 7+8 3 2 3+4 1 
 937 2 3 
3+
4 
2+
3 
2+
3 
3+
5 
3 1+2 2 3+4 2+4 2 2 3+5 1 5 3 2+3 3 3 8+9 2+3 2 3+5 1 
 947 2 3 4 3 
2+
4 
3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 9 2 2 4 1 
 953 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 2+3 3 8 2 2 4 1 
 954 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 7+9 2 2 4 2 
 970 2 4 
3+
4 
2 3 
3+
4 
3 3+5 2 3+4 4 4 2 5 1 5+7 3 3 3+5 3 8 2+3 2+3 3+4 1 
 978 2 4 3 2 3 4 3 1+3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 1 
 979 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 2+3 2 
 1084 2 3 4 3 4 3 3 1 2 2+4 4 2 2 5 1 5 3 2 3 3 9 2 2 4 1 
 1085 2 3 4 3 4 3 3 1 2 4 4 2 2 5 1 5 3 2 3 3 5+9 2 2 4 1 
970  2 4 
3+
4 
2 3 
3+
4 
3 3+5 2 3+4 4 4 2 5 1 5+7 3 3 3+5 3 8 2+3 2+3 3+4 1 
 374 2 4 3 2 3 3 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 4 
 379 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 2 2 3 1 
 382 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 89 
 523 2 4 4 2 3 3 3 5 2 3 4 4 2 5 1 7 3 3 5 3 8 2 3 4 1 
 825 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 1 
 838 2 
3+
4 
3+
4 
2+
3 
3+
4 
3+
4 
3 1+3 2 3+4 4 2+4 2 5 1 5 3 2+3 3 3 8+9 2+3 2 3+4 1 
 978 2 4 3 2 3 4 3 1+3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 3 1 
 979 2 4 3 2 3 4 3 3 2 3 4 4 2 5 1 5 3 3 3 3 8 3 2 2+3 2 
105
2 
 2 
2+
4 
3+
4 
2 3 
4+
5 
3 3+4 2 2+3 2+4 2+3 2 3+6 1 5 3 1+3 3 1+3 7 2+3 2 4 1 
102 
 
 132 2 2 3 2 3 5 3 3 2 2 2 3 2 3 1 5 3 3 3 3 7 3 2 4 4 
 138 2 2 3 2 3 5 3 3 2 3 2 3 2 3 1 5 3 3 3 3 7 3 2 4 16 
 202 2 2 4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 10 
 558 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 40 
 661 2 2 3 2 3 5 3 3 2 3 2 3 2 3 1 5 3 3 3 3 7 3 2 4 9 
 727 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 2 
 840 2 
1+
2 
3+
4 
2 
1+
3 
3+
5 
3 2+3 2 3 2+4 2+3 2 6 1 5 3 3 3 3+5 5+7 2+3 2 4+5 1 
 855 2 
3+
4 
4 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 7 2 2 4 1 
 980 2 4 3 2 3 4 3 4 2 2 4 2 2 6 1 5 3 1 3 1 6+7 2 2 4 1 
 1006 2 4 4 2 3 
3+
4 
3 4 2 2+3 4 2+4 2 5+6 1 5+7 3 1+3 3+5 1 7+8 2 2+3 4+5 1 
 1012 2 4 4 2 3 4 3 4 2 2 4 2 2 6 1 4+5 3 1 3 1 7 2 2 4 1 
 1052 2 
2+
4 
3+
4 
2 3 
4+
5 
3 3+4 2 2+3 2+4 2+3 2 3+6 1 5 3 1+3 3 1+3 7 2+3 2 4 1 
105
4 
 2 
1+
4 
4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 3+5 3 2 4 2 2 4 1 
 445 2 4 4 2 1 3 1 3 2 2 4 1 1 6 1 5 2 5 3 2 4 2 2 4 1 
 1053 2 
1+
4 
4 2 1 3 1 3 2 2 4+5 1 1+2 6 1 5 2 3+5 3 2 4+9 2 2 4 1 
 
 
  
103 
 
Table 13. Transmission Mechanism of Mixed Tuberculosis Infection I. Unique reactivated strains + Unique reactivated strains (N = 10) 
Mix
ed 
Infe
ctio
n 
MIR
UID 
Asso
ciate
d 
Strai
n 
MIRU
ID 
v_
_1
54 
v_
_4
24 
v_
_5
77 
v_
_5
80 
v_
_8
02 
v_
_9
60 
v__
164
4 
v__
195
5 
v__
205
9 
v__
216
5 
v__
234
7 
v__
240
1 
v__
246
1 
v__
253
1 
v__
268
7 
v__
299
6 
v__
300
7 
v__
317
1 
v__
319
2 
v__
369
0 
v__
405
2 
v__
415
6 
v__
434
8 
v__
216
3b 
Freq
uenc
y 
861 . 2 1 3 1 1   2+3 3 2 3 2 1 2 3 1 5 3 3 3 3 5 3 2 3+5 1 
946 . 2 3 4 2 3     3 2   4 3 2 5 1 5+7 3 4 3+5 3 5 2 3 4 1 
856 . 2 1+
2 
4 2 4 3 1+3 2 2 2 3+4 2 2+3 5+6 1 5 3 3 3 3 4 2 2 2 1 
850 . 2 2+
4 
4 2 2+
3 
3+
4 
3+4 2+3 2 2 4 2+4 2 5 1 4+5 3 3 3 2 5 2+3 2 3+6 1 
102
4 
. 2 5 4 2 1 4 1 2 2 2 4 1 1 4 1 5 2 5 2+3 2 6+7 2 2 3 1 
885 . 2 2 3 2 3 3+
5 
3 2 2 2+3 2 3   3 1 2 3 3 3 4 9 3 1 5 1 
839 . 2 2+
3 
2+
4 
2+
5 
3 3+
4 
3 5 2 4 3+4 2+4 2+4 5+6 1+2 2+7 3 3 5 3 3+6 1+2 1+3 3+6 1 
854 . 2 1+
4 
4 2 3 3 1 5 2 3 4 4 1+2 4 1 7 4 1+5 3 2+3 9 1 2 4 1 
106
0 
. 2 1 4 2 1 3 2 3 2 1 4+5 1 2 6 1 5 3 1+3 3 1+2 4 2 2 2 1 
107
7 
. 2 2 4 2+
3 
3+
4 
3+
5 
3 1+2 2 3+4 2+4 2+3 2 3+5 1 5 3 2+3 3 3 8 2+3 2 4 1 
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Table 14. A genotype and spatial link between a mixed tuberculosis patient and patients with an associated tuberculosis strain within 
the150m radius buffer 
Index Mixed 
Strain 
Matched 
Strains 
Unmatched 
Strains 
Strain 
Type 
MIRU ID 
Strain 
Prevalence 
TB 
Diagnosis 
HIV 
Infection 
TB 
History 
A   Mixed 970 1 (0.0%) 9/2/2013 Positive None 
 B  Single 382 81 (3.8%) 5/16/2013 Positive None 
 C  Single 382 81 (3.8%) 5/8/2015 Positive None 
  D Single 138 14 (0.7%) 4/1/2014 Positive Yes 
  E Single 274 15 (0.7%) 5/23/2013 Positive None 
  F Single 274 15 (0.7%) 6/10/2013 Positive None 
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Figures 
Figure 6. Genotypic cluster and non-cluster examples 
 
The figure shows a haploid circular Mycobacterium tuberculosis (MTB) genome. Among 24 loci of 
variable numbers of tandem repeats, it presents five loci. The numbers of tandem repeats at other 19 
loci are assumed to be matched. Two MTB genomes (Strain A and B) in the genotypic cluster example on 
the top row had matched tandem repeats at all five loci (Strain A: 2+3+3+1+…+4, Strain B: 
2+3+3+(1+3)+…+4) compared with the mixed infection MTB genome (2+(1+3)+3+(1+2)+…+4). Strain B 
and mixed infection strain had different set of tandem repeats at locus 4, but the tandem repeat one 
can partially explain the mixed infection, and hence included in the genotypic cluster. The other MTB 
genomes (Strain C and D) in the genotypic non-cluster example at the below row had non-matched 
tandem repeats at locus 4 for C and at locus 3 for D.  
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Figure 7. Distribution of the tuberculosis patients in Gaborone 
 
 
 
 
 
 
 
 
 
 
Distribution of the tuberculosis patients based on their residential address in Gaborone. There were 37 
mixed infection patients and 412 patients with genotypic clustered strains. 
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Figure 8. A genotype and spatial link between a mixed tuberculosis patient (A) and the two patients 
with an associated tuberculosis strain (B and C) within the150m radius buffer  
 
First figure shows the distribution of TB patients in a part of south-east district in Gaborone. Second 
figure shows the distribution of mixed TB infection patient A and other patients who were infected with 
MTBs genotypic matched to patient A’s mixed MTB strains. Third figure shows the patient A and patient 
B and C whose MTB strains were matched to patient A’s, whose location based on the residential 
address was within 150m from the patient A, and who were diagnosed TB within two years from the 
patient A. 
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Chapter 5. Conclusions 
Conclusions and implications 
 The emergence of HIV and the new discovery of mixed infection have challenged, but at the same 
time advanced, TB control measures and our knowledge of TB epidemiology. (1,2) The dissertation study 
findings showed that: 1) high community-level ART coverage rate may have a protective effect on the 
incident risk of TB among community residents, 2) intensive ART scale-up, based on long-term predictions, 
would contribute to a big reduction in TB incidence, and 3) a high proportion of mixed infection cases may 
occur through a combination of ongoing transmission and reactivation mechanisms. 
Beyond these primary findings, the dissertation findings deliver a more important message that a 
single intervention or a one-dimensional approach may not solve the remaining TB concerns addressed in 
the studies. Community-level socioeconomic risk factors, in addition to ART coverage, accounts for a 
moderate level of individual TB risk; other interventions than ART scale-are required to meet the 2035 
global target goal; and accounting for reactivation should be incorporated in addition to the current focus 
on interrupting the recent tran/smission chain in high TB burden settings to control and prevent the mixed 
infection epidemic.  
 In summary, the dissertation findings have identified a current research gap and expanded our 
knowledge on interpreting ecological predictors of community-level ART coverage through the individual-
level TB risk perspective, using an agent-based model to predict the long-term effect of ART on TB 
incidence, and exploring possible transmission mechanisms of mixed TB infection. Although the 
dissertation studies were conducted in Botswana, the addressed issues and complexities related to TB are 
not only relevant in Botswana. The findings will provide valuable lessons and recommendations to other 
high TB and HIV burden countries. 
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